US20140081390A1 - Cardiac Valve, System, and Method - Google Patents

Cardiac Valve, System, and Method Download PDF

Info

Publication number
US20140081390A1
US20140081390A1 US14/084,088 US201314084088A US2014081390A1 US 20140081390 A1 US20140081390 A1 US 20140081390A1 US 201314084088 A US201314084088 A US 201314084088A US 2014081390 A1 US2014081390 A1 US 2014081390A1
Authority
US
United States
Prior art keywords
valve
frame
leaflets
support frame
cover
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/084,088
Inventor
Mark L. Jenson
William J. Drasler
Daniel Lafontaine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Scientific Scimed Inc
Original Assignee
Boston Scientific Scimed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Scientific Scimed Inc filed Critical Boston Scientific Scimed Inc
Priority to US14/084,088 priority Critical patent/US20140081390A1/en
Publication of US20140081390A1 publication Critical patent/US20140081390A1/en
Priority to US14/556,960 priority patent/US9918834B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2412Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
    • A61F2/2418Scaffolds therefor, e.g. support stents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2412Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0063Three-dimensional shapes
    • A61F2230/0073Quadric-shaped
    • A61F2230/008Quadric-shaped paraboloidal

Definitions

  • the present invention relates generally to apparatus, systems, and methods for use in a lumen; and more particularly to cardiac valves, systems, and methods for use in the vasculature system.
  • Heart valves Diseases of the heart valves are grouped according to which valve(s) are involved and the way that blood flow is disrupted. The most common valve problems occur in the mitral and aortic valves. Diseases of the tricuspid and pulmonary valves are fairly rare.
  • the aortic valve regulates the blood flow from the heart's left ventricle into the aorta.
  • the aorta is the main vessel that supplies oxygenated blood to the rest of the body.
  • Diseases of the aorta can have a significant impact on an individual. Examples of such diseases include aortic regurgitation and aortic stenosis.
  • Aortic regurgitation is also called aortic insufficiency or aortic incompetence. It is a condition in which blood flows backward from a widened or weakened aortic valve into the left ventricle of the heart. In its most serious form, aortic regurgitation is caused by an infection that leaves holes in the valve leaflets. Symptoms of aortic regurgitation may not appear for years. When symptoms do appear, it is because the left ventricle must work harder as compared to an uncompromised ventricle to make up for the backflow of blood. The ventricle eventually gets larger and fluid backs up.
  • Aortic stenosis is a narrowing or blockage of the aortic valve.
  • Aortic stenosis occurs when the valve leaflets of the aorta become coated with deposits. The deposits change the shape of the leaflets and reduce blood flow through the valve.
  • the left ventricle has to work harder as compared to an uncompromised ventricle to make up for the reduced blood flow. Over time, the extra work can weaken the heart muscle.
  • FIGS. 1A-1D illustrate an embodiment of a valve in perspective view.
  • FIGS. 2A-2B illustrate another embodiment of a valve in perspective view.
  • FIGS. 3A and 3B illustrate another embodiment of a valve in perspective view.
  • FIGS. 4A and 4B illustrate another embodiment of a valve in perspective view.
  • FIG. 5 illustrates an embodiment of a system that includes a valve.
  • FIG. 6 illustrates an embodiment of a system that includes a valve.
  • FIG. 7 illustrates an embodiment of a system that includes a valve.
  • Embodiments of the present invention are directed to an apparatus, system, and method for cardiac valve replacement and/or augmentation.
  • the apparatus can include a cardiac valve that can be used to replace an incompetent valve in a body lumen.
  • Embodiments of the cardiac valve can include a support frame and cover that can be implanted through minimally-invasive techniques into a body lumen, such as an artery or a vein.
  • embodiments of the present invention may help to augment or replace the function of a cardiac valve of individuals having heart valve disease.
  • the cardiac valve can be implanted within the fluid passageway of a body lumen, such as for replacement of a cardiac valve structure within the body lumen (e.g., an aortic valve at the aortic root), to regulate the flow of a bodily fluid through the body lumen in a single direction.
  • a cardiac valve structure within the body lumen (e.g., an aortic valve at the aortic root)
  • FIGS. 1A and 1B illustrate one embodiment of a cardiac valve 100 .
  • FIGS. 1A and 1B provide a perspective illustration of valve 100 in an open configuration ( FIG. 1A ) and a closed configuration ( FIG. 1B ).
  • FIGS. 1C and 1D provide a sectional view of FIGS. 1A and 1B , respectively, to more clearly illustrate the embodiment of the cardiac valve 100 .
  • Cardiac valve 100 includes a support frame 102 and a cover 104 .
  • the support frame 102 includes an outer surface 106 and an inner surface 108 .
  • the support frame 102 further includes a first end member 110 and a second end member 112 opposing the first end member 110 .
  • the first end member 110 and the second end member 112 are in a substantially fixed distance relationship 114 .
  • a substantially fixed distance relationship 114 indicates a fixed distance between the members 110 and 112 that may include variations of the fixed distance relationship inherently resulting from the manufacture of the articles of the present invention.
  • the substantially fixed distance relationship 114 need not be consistent around the circumference of the cardiac valve 100 .
  • the substantially fixed distance relationship 114 can be varied up to a predetermined percentage of an average valve diameter of the substantially fixed distance relationship 114 . In one embodiment, the predetermined percentage can be up to seventy (70) percent (%).
  • the support frame 102 further includes an open frame configuration in which the first end member 110 and the second end member 112 are closed rings that define a sequence of convex curves 116 and concave curves 118 .
  • the sequence of convex curves 116 and concave curves 118 are arranged such that the first end member 110 and the second end member 112 provide mirror images of each other set apart by the substantially fixed distance relationship 114 .
  • the sequence of convex curves 116 and concave curves 118 are arranged such that the first end member 110 and the second end member 112 are substantially parallel.
  • the sequence of convex curves 116 and concave curves 118 are arranged such that the relative position of the first end member 110 and the second end member 112 can have a variation from about zero (0) percent to about two hundred (200) percent variation as compared to an average distance or a preselected distance between the members 110 and 112 .
  • the valve can be about twenty (20) to eighty (80) percent. As will be appreciated, the selection of these percentage values can be based on the anatomical location into which the valve is to be placed. As illustrated in FIGS.
  • the sequence of convex curves 116 and concave curves 118 of the first and second end members 110 and 112 can transition between each other with a uniform radius of curvature for each of the convex curves 116 and concave curves 118 .
  • the sequence of convex curves 116 and concave curves 118 transition between each other in a non-uniform manner.
  • the convex curves 116 can have a radius of curvature that is different (e.g., smaller) than the radius of curvature for the concave curves 118 ( FIGS. 2A and 2B ).
  • the shape and relationship of the convex curves 116 and concave curves 118 for each of the first end member 110 and the second end member 112 need not be symmetrical relative to each other, rather they may provide for a non-symmetrical relationship, which may vary around the circumference.
  • the support frame 102 can further include cross-members 120 coupled to the first end member 110 and the second end member 112 .
  • cross-members 120 help to maintain the first end member 110 and the second end member 112 in the substantially fixed distance relationship 114 .
  • the cross-members 120 can include a cross-sectional shape and can be formed from the same or similar materials as the end members 110 and 112 , as discussed herein.
  • the cross-members 120 can include any number of configurations, including linear configurations in which cross member 120 are arranged in parallel relative to other cross-members 120 . Other configurations include, but are not limited to, curved configurations, configurations including one or more bends in the cross member 120 , and configurations that include coil configurations. Other configurations are also possible.
  • the cross-members 120 can further include additional members spanning between the cross-members 120 and/or the end members 110 and 112 , as will be discussed herein.
  • the support frame 102 can be formed from a wide variety of materials and in a wide variety of configurations.
  • support frame 102 can have a unitary structure with an open frame configuration.
  • the open frame configuration can include frame members (e.g., first end member 110 and a second end member 112 , cross-members 120 ) that define openings 124 through the support frame 102 .
  • the support frame 102 can also be self-expanding. Examples of self-expanding frames include those formed from temperature-sensitive memory alloy which changes shape at a designated temperature or temperature range. Alternatively, the self-expanding frames can include those having a spring-bias.
  • the support frame 102 can have a configuration that allows the frame 102 to be radially expandable through the use of a balloon catheter.
  • the support frame 102 illustrated herein is shown having a circular configuration, other configurations are also possible.
  • the support frame 102 can also include an elliptical configuration, or other configurations that can accommodate the physiological structure in which the support frame 102 is to be placed.
  • the support frame 102 is illustrated as having linear or long curved members, it will be appreciated that the support frame 102 and/or the crossmembers 120 can have a configuration that allows the support frame 102 and/or the cross-members 120 to be flexible. Examples of such configurations include those that are zigzag and/or serpentine so as to allow the frame to be radially compressible. As such, the present invention should not be limited to the illustration of the support frame 102 .
  • the support frame 102 can also provide sufficient contact and expansion force with the surface of a body lumen wall to encourage fixation of the valve 100 and to prevent retrograde flow within the body lumen.
  • Anchoring elements e.g., barbs
  • valve 100 can also be included with valve 100 , as will be discussed herein.
  • the members (e.g., first end member 110 and a second end member 112 , cross-members 120 ) forming support frame 102 can include a variety of cross-sectional shapes and dimensions.
  • cross-sectional shapes for the members 122 can include, but are not limited to, circular, tubular, I-shaped, T-shaped, oval, and triangular.
  • the members can also have a single cross-sectional shape (e.g., all members of support frame 102 can have a circular cross-sectional shape).
  • the members of the support frame 102 can include two or more cross-sectional shapes (e.g., a first cross-sectional shape for both the first end member 110 and a second end member 112 , and a second cross-sectional shape for the cross-members 120 ).
  • the support frame 102 can be formed from any number of materials.
  • the support frame 102 can be formed from a biocompatible metal, metal alloy, polymeric material, or combination thereof.
  • the support frame 102 can be self-expanding or balloon expandable.
  • suitable materials for the support frame 102 include, but are not limited to, medical grade stainless steel (e.g., 316L), titanium, tantalum, platinum alloys, niobium alloys, cobalt alloys, alginate, or combinations thereof.
  • the support frame 102 may be formed from a shape-memory material, such as shape memory plastics, polymers, and thermoplastic materials which are inert in the body. Shaped memory alloys having superelastic properties generally made from specific ratios of nickel and titanium, commonly known as nitinol, are also possible materials. Other materials are also possible.
  • Members (e.g., first end member 110 and a second end member 112 , cross members 120 ) of the support frame 102 can be shaped and joined in any number of ways.
  • a single contiguous member can be bent around an elongate tubular mandrel to form the end members 110 and 112 of the support frame 102 .
  • the free ends of the single contiguous member can then be welded, fused, crimped, or otherwise joined together to form the support frame 102 .
  • the cross-members 120 can be joined to the end members 110 and 112 in a similar manner.
  • the support frame 102 can be derived (e.g., laser cut, water cut) from a single tubular segment.
  • the support frame 102 can be heat set by a method as is typically known for the material which forms the support frame 102 .
  • Support frame 102 and cover 104 can be expanded to provide lumen 126 having any number of sizes.
  • the size of lumen 126 can be determined based upon the type of body lumen and the body lumen size in which the valve 100 is to be placed.
  • the support frame 102 can also include a longitudinal length 130 .
  • the support frame 102 can further include one or more anchoring elements.
  • the one or more anchoring elements can include, but are not limited to, one or more barbs 132 projecting from the outer surface 106 of the support frame 102 .
  • the valve 100 can further include one or more radiopaque markers (e.g., tabs, sleeves, welds).
  • one or more portions of the valve frame 102 can be formed from a radiopaque material.
  • Radiopaque markers can be attached to and/or coated onto one or more locations along the support frame 102 . Examples of radiopaque material include, but are not limited to, gold, tantalum, and platinum.
  • the position of the one or more radiopaque markers can be selected so as to provide information on the position, location and orientation of the valve 100 during its implantation.
  • the cover 104 of the cardiac valve 100 forms valve leaflets 133 having surfaces defining a reversibly sealable opening 134 for unidirectional flow of a liquid through the valve 100 .
  • the cover 104 can extend across an area between the convex curves 116 and the concave curves 118 of the second end member 112 to form valve leaflets 133 of the cardiac valve 100 .
  • the position and number of the convex and concave curves 116 and 118 in the second end member 112 determine the number of valve leaflets 133 of the cardiac valve 100 .
  • FIGS. 1A and 1B provide a bi-leaflet cardiac valve according to an embodiment of the present invention.
  • cover 104 extends across the area between a first convex curve 136 and a second convex curve 138 and down to the concave curves 118 of the second end member 112 to form a first valve leaflet 140 and a second valve leaflet 142 .
  • first convex curve 136 and the second convex curve 138 of the second end member 112 are positioned opposite each other along a common axis 144 .
  • the common axis 144 bisects support frame 102 into symmetrical portions.
  • the first valve leaflet 140 and the second valve leaflet 142 each display substantially the same shape, size and configuration as each other.
  • the first convex curve 136 and the second convex curve 138 can be positioned so that the common axis 144 divides the support frame 102 into non-symmetrical portions.
  • the first valve leaflet 140 and the second valve leaflet 142 can have different shapes, sizes and configurations relative to each other.
  • the cover 104 also extends over the first end member 110 . In contrast to the second end member 112 , however, the cover 104 terminates along the convex and concave curves 116 and 118 of the first end member 110 so as to define an open area 146 between the sequence of convex curves 116 and concave curves 118 . As will be more fully discussed below, providing the open area 146 allows the valve 100 to accommodate the anatomical structures of the autologous valve being replaced so as to reduce any potential interference with anatomical structures adjacent the autologous valve (e.g., the coronary ostia located adjacent aortic valve).
  • anatomical structures adjacent the autologous valve e.g., the coronary ostia located adjacent aortic valve.
  • the second end member 112 can include additional convex curves 116 and the concave curves 118 so as to provide support structures for additional valve leaflets 133 (e.g., a tri-leaflet valve).
  • the cover 104 in conjunction with the support frame 102 defines the lumen 126 of the cardiac valve 100 for passing fluid (e.g., blood) there-through.
  • the cover 104 further includes surfaces defining a reversibly sealable opening 134 for unidirectional flow of a liquid through the lumen 126 .
  • a portion of the first valve leaflet 140 and the second valve leaflet 142 can join to form the reversibly sealable opening 134 for unidirectional flow of a liquid through the cardiac valve 100 .
  • FIGS. 1A and 1B illustrate embodiments in which the surfaces of the cover 104 can be deflectable between a closed configuration ( FIG. 1B ) in which fluid flow through the lumen 126 can be restricted and an open configuration ( FIG. 1A ) in which fluid flow through the lumen 126 can be permitted.
  • the first valve leaflet 140 and the second valve leaflet 142 can move relative the support frame 102 (i.e., the first valve leaflet 140 and the second valve leaflet 142 are attached to and pivot along the support frame 102 ).
  • the cover 104 provides sufficient excess material spanning support frame 102 to allow the first valve leaflet 140 and the second valve leaflet 142 to join sealing surfaces 148 at the reversibly sealable opening 134 .
  • the reversibly sealable opening 134 formed by the first and second valve leaflets 140 and 142 opens and closes in response to the fluid pressure differential across the valve leaflets 140 and 142 . That is, antegrade blood flow causes the valve leaflets to open, thereby providing for unidirectional blood flow through the reversibly sealable opening. In contrast, retrograde blood flow causes the valve leaflets close, thereby preventing blood flow from passing through the reversibly sealable opening.
  • the first valve leaflet 140 and the second valve leaflet 142 further include arcuate edges 150 and 152 that are positioned adjacent each other along a substantially catenary curve between the first convex curve 136 and the second convex curve 138 of the second end member 112 in the closed configuration ( FIG. 1B ) of valve 100 .
  • arcuate edges 150 and 152 can form the reversibly sealable opening 134 when the valve 100 is in the open configuration ( FIG. 1A ).
  • first and second valve leaflets 140 and 142 can expand toward the support frame 102 to create an opening through which fluid is permitted to move.
  • first valve leaflet 140 and the second valve leaflet 142 can each expand to form a semi-tubular structure when fluid opens the reversibly sealable opening 134 .
  • arcuate edge 150 and 152 of valve 100 can open to approximately the full inner diameter of a body lumen. An example of the open configuration for the valve is shown in FIG. 1A .
  • the first and second valve leaflets 133 extend a variable distance beyond the second end member 112 .
  • valve leaflets 140 and 142 Under a retrograde fluid flow (i.e., negative fluid pressure) moving from the second end member 112 towards the first end member 110 , the first and second valve leaflets 140 and 142 move away from the support frame 102 as the valve leaflets 140 and 142 begin to close.
  • the valve leaflets 140 and 142 include a predefined shape that allows for the retrograde fluid flow to develop pressure on a major surface 154 of the first and second valve leaflets 140 and 142 .
  • the major surface 154 can have a concave shape 156 to better collect retrograde fluid flow to urge the first valve leaflet 140 and the second valve leaflet 142 towards the closed configuration.
  • the first and second valve leaflets 140 and 142 move towards each other eventually forming the reversibly sealable opening 134 (i.e., closing the valve 100 ), thereby restricting retrograde fluid flow through the valve 100 .
  • FIGS. 1B and 1D when the valve leaflets 140 , 142 obstruct the lumen 126 of the valve, the valve leaflets 140 , 142 do not extend a variable distance beyond the second end member 112 .
  • the valve leaflets 140 , 142 are substantially perpendicular to the longitudinal axis of the valve.
  • first valve leaflet 140 and the second valve leaflet 142 can include one or more support structures, where the support structures can be integrated into and/or onto the valve leaflets 140 and 142 .
  • first valve leaflet 140 and the second valve leaflet 142 can include one or more support ribs having a predetermined shape.
  • the predetermined shape of the support ribs can include a curved bias so as to provide the first valve leaflet 140 and the second valve leaflet 142 with a curved configuration.
  • Support ribs can be constructed of a flexible material and have dimensions (e.g., thickness, width and length) and cross-sectional shape that allows the support ribs to be flexible when the first valve leaflet 140 and the second valve leaflet 142 are urged into an open position upon experiencing sufficient blood flow pressure from the direction upstream from the valve, e.g., antegrade blood flow, and stiff when the first valve leaflet 140 and the second valve leaflet 142 are urged into a closed position upon experiencing sufficient back flow pressure from the direction downstream from the valve, e.g., retrograde blood flow.
  • support ribs can also be attached to support frame 102 so as to impart a spring bias to the valve leaflets 133 in either the open or the closed configuration.
  • cover 104 used to form the valve leaflets 140 and 142 can be constructed of a material sufficiently thin and pliable so as to permit radially-collapsing of the valve leaflets for delivery by catheter to a location within a body lumen.
  • the cover 104 can be constructed of a biocompatible material that can be either synthetic or biologic or a combination of synthetic and biologic biocompatible material.
  • Possible synthetic materials include, but are not limited to, expanded polytetrafluoroethylene (ePTFE), polytetrafluoroethylene (PTFE), polystyrene-polyisobutylene-polystyrene (SIBS), polyurethane, segmented poly(carbonate-urethane), polyester, polyethlylene (PE), polyethylene terephthalate (PET), silk, urethane, Rayon, Silicone, or the like.
  • the synthetic material can also include metals, such as stainless steel (e.g., 316L) and nitinol. These synthetic materials can be in a woven, a knit, a cast or other known physical fluid-impermeable or permeable configurations.
  • Possible biologic materials include, but are not limited to, autologous, allogeneic or xenograft material. These include explanted veins, pericardium, facia lata, harvested cardiac valves, bladder, vein wall, various collagen types, elastin, intestinal submucosa, and decellularized basement membrane materials, such as small intestine submucosa ( 515 ), amniotic tissue, or umbilical vein.
  • the cover 104 can be located over at least the outer surface 106 of the support frame 102 .
  • FIGS. 1A-1D provide one illustration of this embodiment.
  • the leaflets 133 extend from the portion of the cover extending over the support frame 102 .
  • the cover 104 can be located over at least the inner surface 108 of the support frame 102 .
  • FIGS. 2A-2B provide a cross-sectional perspective view of cover 204 extending over both an inner surface 208 and the outer surface 206 of the support frame 202 to form the bi-leaflet cardiac valve.
  • the cover 204 can further be located over the openings 224 defined by the members of the support frame 202 .
  • the cover 204 can also be joined to itself through the openings 224 so as to fully or partially encase the support frame 202 .
  • cover 204 may be laminated or bond on the outer surface 206 and/or the inner surface 208 of the support frame 202 , including heat setting, adhesive welding, interlocking, application of uniform force and other bonding techniques. Additionally, the cover 204 may be folded over the first end member 210 of the support frame 202 to provide the cover 204 on both the outer surface 206 and the inner surface 208 . Cover 204 can also be joined to itself and/or the members according to the methods described in U.S. Patent Application Publication US 2002/0178570 to Sogard et al.
  • the valve 200 can further include a layer of material 258 positioned between the cover 204 extending over the inner surface 208 and the outer surface 206 of the support frame 202 .
  • the layer of material 258 can be formed from the biocompatible material used for the cover 204 .
  • the layer of material 258 can be structurally different than the material of cover 204 .
  • cover 204 can include a fluid permeable open woven, or knit, physical configuration to allow for tissue in-growth and stabilization, whereas the layer of material 258 can have a fluid impermeable physical configuration.
  • Examples of the material 258 include, but are not limited to, the synthetic materials described herein. Other combinations of physical configurations for the cover 204 and the layer of material 258 are also possible.
  • the support frame 102 and/or the cover 104 may also be treated and/or coated with any number of surface or material treatments.
  • suitable bioactive agents which may be incorporated with or utilized together with the present invention may be selected from silver antimicrobial agents, metallic antimicrobial materials, growth factors, cellular migration agents, cellular proliferation agents, anti-coagulant substances, stenosis inhibitors, thrombo-resistant agents, antibiotic agents, anti-tumor agents, anti-proliferative agents, growth hormones, antiviral agents, anti-angiogenic agents, angiogenic agents, cholesterol-lowering agents, vasodilating agents, agents that interfere with endogenous vasoactive mechanisms, hormones, their homologs, derivatives, fragments, pharmaceutical salts and combinations thereof.
  • the most useful bioactive agents can include those that modulate thrombosis, those that encourage cellular ingrowth, throughgrowth, and endothelialization, those that resist infection, and those that reduce calcification.
  • coating treatments can include one or more biologically active compounds and/or materials that may promote and/or inhibit endothelial, smooth muscle, fibroblast, and/or other cellular growth onto or into the support frame 102 and/or the cover 104 , including the valve leaflets 140 and 142 .
  • examples of such coatings include, but are not limited to, polyglactic acid, poly-L-lactic acid, glycol-compounds, and lipid compounds.
  • coatings can include medications, genetic agents, chemical agents, and/or other materials and additives.
  • agents that limit or decrease cellular proliferation can be useful.
  • the support frame 102 and/or the cover 104 may be seeded and covered with cultured tissue cells (e.g., endothelial cells) derived from a either a donor or the host patient which are attached to the valve leaflets 140 and 142 .
  • the cultured tissue cells may be initially positioned to extend either partially or fully over the valve leaflets 140 and 142 .
  • Cover 104 in addition to forming valve leaflets 140 and 142 , can also be capable of inhibiting thrombus formation, as discussed herein. Additionally, cover 104 may either prevent or facilitate tissue ingrowth there-through, as the particular application for the valve 100 may dictate. For example, cover 104 on the outer surface 106 may be formed from a porous material to facilitate tissue ingrowth there-through, while cover 104 on the inner surface 108 maybe formed from a material or a treated material which inhibits tissue ingrowth.
  • Cells can be associated with the present invention.
  • cells that have been genetically engineered to deliver bioactive proteins, such as the growth factors or antibodies mentioned herein, to the implant site can be associated with the present invention.
  • Cells can be of human origin (autologous or allogenic) or from an animal source (xenogenic).
  • Cells can be pre-treated with medication or preprocessed such as by sorting or encapsulation.
  • the delivery media can be formulated as needed to maintain cell function and viability.
  • Thrombo-resistant agents associated with the valve may be selected from, but not limited to, heparin, heparin sulfate, hirudin, hyaluronic acid, chondroitin sulfate, dermatan sulfate, keratin sulfate, PPack (detropyenylalanine praline arginine chloromethylketone), lytic agents, including urokinase and streptokinase, their homologs, analogs, fragments, derivatives and pharmaceutical salts thereof.
  • Anti-coagulants can include, but are not limited to, D-Phe-Pro-Arg chloromethyl ketone, an RGD peptide-containing compound, heparain, antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors, tick antiplatelet peptides and combinations thereof.
  • Antibiotic agents can include, but are not limited to, penicillins, cephalosportins, vancomycins, aminoglycosides, quinolonges, polymyxins, erythromycins, tetracyclines, chloraphenicols, clindamycins, lincomycins, sulfonamides, their homologs, analogs, derivatives, pharmaceutical salts and combinations thereof.
  • Anti-proliferative agents for use in the present invention can include, but are not limited to, the following: paclitaxel, sirolimus, everolimus, or monoclonal antibodies capable of blocking smooth muscle cell proliferation, related compounds, derivatives, and combinations thereof.
  • Vascular cell growth inhibitors can include, but are not limited to, growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of a an antibody and a cytotoxin.
  • Vascular cell growth promoters include, but are not limited to, transcriptional activators and transcriptional promoters.
  • Anti-inflammatory agents can include, but are not limited to, dexametbasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazinemesalamne, and combinations thereof.
  • FIGS. 3A and 3B illustrate an additional embodiment of a cardiac valve 300 .
  • FIGS. 3A and 3B provide a perspective illustration of valve 300 having three valve leaflets 333 in an open configuration ( FIG. 3A ) and a closed configuration ( FIG. 3B ).
  • cardiac valve 300 includes the support frame 302 having the first end member 310 and the second end member 312 opposing the first end member 310 in the substantially fixed distance relationship 314 .
  • the cover 304 of the cardiac valve 300 forms a tri-leaflet valve having surfaces defining the reversibly sealable opening 334 for unidirectional flow of a liquid through the valve 300 . As illustrated, FIGS.
  • 3A and 3B provide a tri-leaflet cardiac valve in which cover 304 extends across the area between the first convex curve 336 , the second convex curve 338 , and a third convex curve 364 , and down to the concave curves 318 of the second end member 312 to form the first valve leaflet 340 , the second valve leaflet 342 , and a third valve leaflet 366
  • the convex curves 336 , 338 , and 364 can lay on a common plane 368 , as illustrated in FIGS. 3A and 3B .
  • the convex curves 336 , 338 , and 364 can lay need not all lay on the common plane 368 . It is possible that one or more of the convex curves 336 , 338 , and 364 can lie above and/or below the common plane 368 .
  • the convex curves 336 , 338 , and 364 can be positioned at equal distances around the second end member 312 . As a result, the valve leaflets 336 , 338 , and 364 each display substantially the same shape, size and configuration as each other.
  • the convex curves 336 , 338 , and 364 can be positioned at one or more unequal distances around the second end member 312 .
  • the valve leaflets 336 , 338 , and 364 can each have different shapes, sizes and configurations relative to each other.
  • the cover 304 in conjunction with the support frame 302 defines the lumen 326 of the cardiac valve 300 for passing fluid (e.g., blood) there-through.
  • the cover 304 can further include surfaces defining the reversibly sealable opening 334 for unidirectional flow of a liquid through the lumen 326 .
  • a portion of the first valve leaflet 340 , the second valve leaflet 342 , and the third valve leaflet 366 can join to form the reversibly sealable opening 334 for unidirectional flow of a liquid through the cardiac valve 300 .
  • FIGS. 3A and 3B illustrate embodiments in which the valve leaflets 340 , 342 , and 366 can deflect between a closed configuration ( FIG. 3B ) in which fluid flow through the lumen 326 can be restricted and an open configuration ( FIG. 3A ) in which fluid flow through the lumen 326 can be permitted.
  • the first valve leaflet 340 , the second valve leaflet 342 , and the third valve leaflet 366 can move relative the support frame 302 between the open configuration and the closed configuration.
  • the cover 304 provides sufficient excess material spanning support frame 302 to allow the valve leaflets 340 , 342 , and 366 to join sealing surfaces 348 at a reversibly sealable opening 334 .
  • the reversibly sealable opening 334 formed by the first, second, and third valve leaflets 340 , 342 , and 366 opens and closes in response to the fluid pressure differential across the valve leaflets.
  • the valve leaflets 340 , 342 , and 366 each include concave surfaces 370 projecting from the support frame 302 towards an arcuate edge 372 projecting into the lumen 326 . As discussed, the valve leaflets 340 , 342 , and 366 can have approximately the same size and shape.
  • the arcuate edge 372 of the valve leaflets 340 , 342 , and 366 can each further include a nodular interruption 374 at approximately the center 376 of the arcuate edge 372 to allow the edges of the leaflets 340 , 342 , and 366 to properly meet as the valve closes.
  • valve leaflets 340 , 342 , and 366 can fall into the lumen to close the reversibly sealable opening 334 and support the column of fluid (e.g., blood).
  • fluid e.g., blood
  • the valve leaflets 340 , 342 , and 366 can expand or move toward the support frame 302 to create an opening through which fluid is permitted to move.
  • the valve leaflets 340 , 342 , and 366 can each expand or move to form a semi-tubular structure when fluid opens the reversibly sealable opening 334 .
  • the valve leaflets 340 , 342 , and 366 can include one or more support structures (e.g., support ribs), as discussed herein.
  • Cover 304 can extend over at least the outer surface 306 of the support frame 302 to form the valve leaflets of the tri-leaflet cardiac valve.
  • cover 304 can also be located over at least the inner surface 308 of the support frame 302 to form the valve leaflets of the tri-leaflet cardiac valve.
  • the cover 304 can be joined to the support frame 302 and itself as discussed herein.
  • the valve 300 can further include a layer of material 358 positioned between the cover 304 extending over the inner surface 308 and the outer surface 306 of the support frame 302 .
  • the cover 304 including the valve leaflets 340 , 342 , and 366 , may also be treated and/or coated with any number of surface or material treatments, as discussed herein.
  • FIGS. 4A and 4B illustrate a further embodiment of a cardiac valve 400 .
  • FIGS. 4A and 4B provide a perspective illustration of valve 400 in an open configuration ( FIG. 4A ) and a closed configuration ( FIG. 4B ).
  • the valve 400 the support frame 402 and the cover 404 that forms valve leaflets having surfaces defining a reversibly sealable opening 434 for unidirectional flow of a liquid through the valve 400 .
  • the present embodiment further includes an elongate tubular member 482 having a first end 484 and a second end 486 .
  • the elongate tubular member 482 can be positioned relative the support frame 402 to allow the first end 484 of the member 482 to be on a first side of the valve leaflets and the second end 486 on a second side of the valve leaflets.
  • the tubular member 482 can pass through an opening in a valve leaflet, where the tubular member 482 and the valve leaflet form a fluid tight seal.
  • the tubular member 482 passes through a region of the reversibly sealable opening 434 , where the leaflets seal around the tubular member 482 when they are in their closed position.
  • the tubular member 482 can be positioned within the opening defined by the support frame 402 .
  • the tubular member 482 can be positioned outside of the support frame 402 .
  • the tubular member 482 can allow fluid communication across the valve 400 when the valve leaflet 433 are in their closed position. In one embodiment, the tubular member 482 can allow for blood at an arterial pressure to be supplied from a region distal to the valve 400 to vessels located proximal the valve 400 . In one embodiment, the tubular member 482 can allow the valve 400 to be positioned at a more convenient and/or less-diseased location in the vasculature (e.g., the aorta) while still allowing blood at arterial pressure to be supplied to the appropriate coronary arteries (e.g., via the coronary ostium).
  • the vasculature e.g., the aorta
  • the tubular member 482 can include any number of physical configurations.
  • the tubular member 482 can include a predetermined length and a predetermined bend 483 to allow the second end 486 of the tubular member 482 to be implanted in a desired location. Examples of such locations include, but are not limited to, a coronary ostium.
  • the predetermined length of the tubular member 482 can be in a range from 10 mm to 50 mm, where the length of the tubular member 482 will be determined based on where the valve 400 is being implanted along with the patient's individual physiological parameters and measurements.
  • the valve 400 can include more than one tubular member 482 .
  • the valve 400 can include two or more tubular members 482 , each tubular member supplying a coronary artery of the patient's vasculature.
  • each of the tubular members 482 can have similar or distinct physical characteristics (e.g., length, inner/outer diameter, predetermined shape).
  • each of the tubular members 482 can further include one or more radiopaque marks to allow each tubular member 482 to be uniquely identified.
  • the tubular member 482 can further include a predetermined shape.
  • the predetermined shape can be determined by the anatomical location in which the valve 400 is being placed along with the anatomical location in which the second end 486 of the tubular member 482 is to be placed.
  • the tubular member 482 can include combinations of linear and bend portions imparted into the tubular member 484 (e.g., the predetermined bend 483 illustrated in FIG. 4B .).
  • the tubular member 482 can be constructed of a material having sufficient flexibility so as to permit the second end 486 of the tubular member 482 to remain positioned in its proper anatomical location within the patient, while also being flexible enough to allow the first end 484 to move radially with the valve leaflet.
  • the tubular member 482 can be constructed of a biocompatible material that can be either synthetic or biologic. Examples of these materials include those discussed herein for the cover 404 .
  • the material used in the construction of the tubular member 484 can be the same or a different material used for the construction of the cover 404 .
  • the tubular member 482 can also include a stent support structure to help maintain a predetermined shape of the tubular member 482 .
  • the tubular member 482 further includes an inner diameter 488 and outer diameter 490 .
  • the inner diameter 488 can be in a range of 2.0 mm to 5.5 mm. Alternatively, the inner diameter 488 can be in a range of 3.0 mm to 4.5 mm. In one embodiment, the dimension of the inner diameter 488 will typically be a function of the volume of fluid flow that is desired to move through the tubular member 484 . The dimension for the outer diameter 490 will be dependent upon the wall thickness of the tubular member 482 required to provide proper flexibility and rigidity to maintain its position once placed in the patient.
  • the embodiments of the valve of the present invention can be formed in any number of ways.
  • a support frame and a cover are both provided for forming the cardiac valve.
  • the cover can have a cylindrical shape of essentially uniform inner diameter, where the inner diameter of the cover is approximately the same size as an outer diameter of the support frame.
  • the cover can be positioned over the outer surface of the support frame.
  • the cover can be stretched slightly to allow the support frame to be placed within the cover.
  • the outer diameter of the tubular frame could be enlarged so as to place the cover around the outer surface of the support frame.
  • Other ways of placing the cover around the outer surface of the support frame are also possible, including placing the cover around both the inside and the outside of the frame.
  • the cover can be positioned over and attached to the support frame so that the cover extends between the convex curves of the second end member to form the valve leaflets.
  • the support frame includes the first convex curve and the second convex curve along the second end member. Providing cover over the support frame then forms the first valve leaflet and the second valve leaflet of the cardiac valve.
  • the cover can also be trimmed along the first end member so as to define the open area between the sequence of convex curves and concave curves along the first end member.
  • the cover can include a first end having a series of convex and concave curves that correspond to those of the first end member so as to provide the open area.
  • the cardiac valve can be formed by providing support frame and cover, where the second end member of support frame includes the first convex curve, the second convex curve, and the third convex curve.
  • Cover can include cylindrical shape that has a second end having a predetermined shape that allows for the formation of the valve leaflets of the tri-leaflet cardiac valve.
  • the second end can also include arcuate edges each having the optional nodular interruption.
  • the cover further includes concave surfaces, as described herein, which can be imparted into the cover through any number of manufacturing processes, including, but not limited to, thermo-molding, heat setting, and chemical cross-linking. As discussed herein, this example of the cover permits the valve leaflets to be created once the cover is properly positioned on the support frame.
  • the cover can also be positioned over both the outer surface and the inner surface of the support frame.
  • two covers can be positioned on the support frame to provide an embodiment of the cardiac valve, or a longer cover can be used over the support frame.
  • additional material can be positioned between the two covers at least in the area between the convex and concave curves of the second end member.
  • one or more flexible support ribs having a predetermined shape could also be incorporated into the cover in forming the concave surfaces.
  • the cover configuration having the arcuate edges, nodular interruptions, and the concave surfaces permits the valve leaflets to be created once the cover is properly positioned over the support frame. The cover can then be affixed to the support frame and itself as discussed herein.
  • the cover can also be trimmed along the first end member so as to define the open area between the sequence of convex curves and concave curves along the first end member.
  • the first end of cover can include a series of convex and concave curves that correspond to those of the first end member so as to provide the open area.
  • surfaces defining the opening through or around the cover can also be provided on the cardiac valve.
  • the tubular member can then be coupled in fluid tight communication to the opening to provide fluid communication with the opening around or through the cover.
  • the first end of the tubular member can be coupled to the support frame with the opening and the lumen of the tubular member aligned so that fluid can move through the opening and the tubular member once the valve has been implanted in a patient.
  • the tubular member can be positioned in the patient, independent of the valve and then subsequently coupled to the valve once the valve has been implanted in the patient.
  • the tubular member allows for the valve to be positioned in any number of locations within the vasculature while still allowing fluid communication with adjacent physiological structures.
  • valve could be implanted in the aorta of a patient downstream of the coronary ostia.
  • the tubular member can be positioned with the second end of the tubular member in the coronary ostia so as to supply arterial blood at arterial pressures to the coronary arteries.
  • FIG. 5 illustrates one embodiment of a system 509 .
  • System 509 includes valve 500 , as described herein, reversibly joined to a delivery catheter 511 .
  • the delivery catheter 511 includes an elongate body 513 having a proximal end 515 and a distal end 517 , where valve 500 can be located between the proximal end 515 and distal end 517 .
  • the delivery catheter 511 can further include a lumen 519 longitudinally extending to the distal end 517 . In one embodiment, lumen 519 extends between proximal end 515 and distal end 517 of catheter 511 .
  • the catheter 511 can further include a guidewire lumen 521 that extends within the elongate body 513 , were the guidewire lumen 521 can receive a guidewire for positioning the catheter 511 and the valve 500 within a body lumen (e.g., the aorta of a patient).
  • a body lumen e.g., the aorta of a patient.
  • the system 509 can further include a deployment shaft 523 positioned within lumen 519 , and a sheath 525 positioned adjacent the distal end 517 .
  • the valve 500 can be positioned at least partially within the sheath 525 and adjacent the deployment shaft 523 .
  • the deployment shaft 523 can be moved within the lumen 519 to deploy valve 500 .
  • deployment shaft 523 can be used to push valve 500 from sheath 525 in deploying valve 500 .
  • FIG. 6 illustrates an additional embodiment of the system 609 .
  • the catheter 611 includes elongate body 613 , lumen 619 , a retraction system 627 and a retractable sheath 629 .
  • the retractable sheath 629 can be positioned over at least a portion of the elongate body 613 , where the retractable sheath 629 can move longitudinally along the elongate body 613 .
  • the valve 600 can be positioned at least partially within the retractable sheath 629 , where the retractable sheath 629 moves along the elongate body 613 to deploy the valve 600 .
  • retraction system 627 includes one or more wires 699 coupled to the retractable sheath 627 , where the wires 699 are positioned at least partially within and extend through lumen 619 in the elongate body 613 . Wires 699 of the retraction system 627 can then be used to retract the retractable sheath 629 in deploying valve 600 .
  • FIG. 7 illustrates an additional embodiment of the system 709 .
  • the catheter 711 includes elongate body 713 , an inflatable balloon 731 positioned adjacent the distal end 717 , and a lumen 735 longitudinally extending in the elongate body 713 of the catheter 711 from the inflatable balloon 731 to the distal end 717 .
  • the inflatable balloon 731 can be at least partially positioned within the lumen 726 of the valve 700 .
  • the inflatable balloon 731 can be inflated through the lumen 735 to deploy the valve 700 .
  • the embodiments of the present invention further include methods for forming the valve of the present invention, as discussed herein.
  • the valve can be formed from the support frame and the cover over at least the outer surface of the support frame, where the cover includes surfaces defining the reversibly sealable opening for unidirectional flow of a liquid through the lumen.
  • the valve can be reversibly joined to the catheter, which can include a process of altering the shape of the valve from a first shape, for example an expanded state, to the compressed state, as described herein.
  • the valve can be reversibly joined with the catheter by positioning valve in the compressed state at least partially within the sheath of the catheter.
  • positioning the valve at least partially within the sheath of the catheter includes positioning the valve in the compressed state adjacent the deployment shaft of the catheter.
  • the sheath of the catheter functions as a retractable sheath, where the valve in the compressed state can be reversibly joined with the catheter by positioning the valve at least partially within the reversible sheath of the catheter.
  • the catheter can include an inflatable balloon, where the balloon can be positioned at least partially within the lumen of the valve, for example, in its compressed state.
  • embodiments of the valve described herein may be used to replace, supplement, or augment valve structures within one or more lumens of the body.
  • embodiments of the present invention may be used to replace an incompetent cardiac valve of the heart, such as the aortic, pulmonary and/or mitral valves of the heart.
  • the method of replacing, supplementing, and/or augmenting a valve structure can include positioning at least part of the catheter including the valve at a predetermined location within an artery of a patient, such as in the aorta adjacent the root of the aortic valve.
  • positioning the valve of the present invention within the aorta particular physiological structures need to be taken into consideration.
  • the valve of the present invention works in conjunction with the coronary artery ostia much in the same way as the native aortic valve. This is accomplished due to the configuration of both the support frame and the cover of the valve as described herein.
  • the configuration of the valve of the present invention permits the valve to be implanted such that the support frame can be positioned between the native aortic valve and the coronary artery ostia.
  • the open area defined by the support frame allows the valve to be seated adjacent the native aortic valve.
  • the valve leaflets of the present invention can be in the same relative position as the native valve leaflets. This allows the valve leaflets of the present invention to interact with the coronary ostia positioned in the aortic sinuses (sinuses of Valsalva) adjacent the aortic valve in the similar manner as the native valve leaflets. So, the valve of the present invention can properly accommodate both the aortic valve and the coronary ostia.
  • positioning the catheter including the valve within the body lumen includes introducing the catheter into the cardiovascular system of the patient using minimally invasive percutaneous, transluminal catheter based delivery system, as is known in the art.
  • a guidewire can be positioned within the cardiovascular system of a patient that includes the predetermined location.
  • the catheter, including valve, as described herein can be positioned over the guidewire and the catheter advanced so as to position the valve at or adjacent the predetermined location.
  • radiopaque markers on the catheter and/or the valve, as described herein can be used to help locate and position the valve.
  • valve of the present invention can be deployed and placed in any number of cardiovascular locations.
  • valve can be deployed and placed within a major artery of a patient.
  • major arteries include, but are not limited to, the aorta.
  • valves of the present invention can be deployed and placed within other major arteries of the heart and/or within the heart itself, such as in the pulmonary artery for replacement and/or augmentation of the pulmonary valve and between the left atrium and the left ventricle for replacement and/or augmentation of the mitral valve. Other locations are also possible.
  • the valve can be deployed from the catheter in any number of ways.
  • the catheter can include the retractable sheath in which valve can be at least partially housed, as discussed herein.
  • Valve can be deployed by retracting the retractable sheath of the catheter, where the valve self-expands to be positioned at the predetermined location.
  • the catheter can include a deployment shaft and sheath in which valve can be at least partially housed adjacent the deployment shaft, as discussed herein.
  • Valve can be deployed by moving the deployment shaft through the catheter to deploy valve from the sheath, where the valve self-expands to be positioned at the predetermined location.
  • the valve can be deployed through the use of an inflatable balloon.
  • the valve can partially self-expand upon retracting a sheath in which the valve is located, and then deployed through the use of an inflatable balloon.
  • the valve can provide sufficient contact and expansion force against the body lumen wall to prevent retrograde flow between the valve and the body lumen wall, and to securely located the valve and prevent migration of the valve.
  • the valve can be selected to have a larger expansion diameter than the diameter of the inner wall of the body lumen. This can then allow valve to exert a force on the body lumen wall and accommodate changes in the body lumen diameter, while maintaining the proper placement of valve.
  • the valve can engage the lumen so as to reduce the volume of retrograde flow through and around valve. It is, however, understood that some leaking or fluid flow may occur between the valve and the body lumen and/or through valve leaflets.
  • the support frame 102 and/or the cover 104 can be coated with a non-thrombogenic biocompatible material, as are known or will be known.
  • Other biologically active agents or cells may also be utilized.

Abstract

A cardiac valve with a support frame having a first end member and a second end member opposing the first end member in a substantially fixed distance relationship, and a cover extending over the support frame to allow for unidirectional flow of a liquid through the valve.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of U.S. application Ser. No. 13/214,520 filed Aug. 22, 2011, which is a continuation of U.S. application Ser. No. 12/508,369 filed Jul. 23, 2009, now U.S. Pat. No. 8,002,824, which is a continuation of U.S. application Ser. No. 10/933,088, now U.S. Pat. No. 7,566,343, filed Sep. 2, 2004, the contents of each are incorporated herein by reference.
  • STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
  • Not Applicable
  • FIELD OF THE INVENTION
  • The present invention relates generally to apparatus, systems, and methods for use in a lumen; and more particularly to cardiac valves, systems, and methods for use in the vasculature system.
  • BACKGROUND OF THE INVENTION
  • Diseases of the heart valves are grouped according to which valve(s) are involved and the way that blood flow is disrupted. The most common valve problems occur in the mitral and aortic valves. Diseases of the tricuspid and pulmonary valves are fairly rare.
  • The aortic valve regulates the blood flow from the heart's left ventricle into the aorta. The aorta is the main vessel that supplies oxygenated blood to the rest of the body. Diseases of the aorta can have a significant impact on an individual. Examples of such diseases include aortic regurgitation and aortic stenosis.
  • Aortic regurgitation is also called aortic insufficiency or aortic incompetence. It is a condition in which blood flows backward from a widened or weakened aortic valve into the left ventricle of the heart. In its most serious form, aortic regurgitation is caused by an infection that leaves holes in the valve leaflets. Symptoms of aortic regurgitation may not appear for years. When symptoms do appear, it is because the left ventricle must work harder as compared to an uncompromised ventricle to make up for the backflow of blood. The ventricle eventually gets larger and fluid backs up.
  • Aortic stenosis is a narrowing or blockage of the aortic valve. Aortic stenosis occurs when the valve leaflets of the aorta become coated with deposits. The deposits change the shape of the leaflets and reduce blood flow through the valve. The left ventricle has to work harder as compared to an uncompromised ventricle to make up for the reduced blood flow. Over time, the extra work can weaken the heart muscle.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIGS. 1A-1D illustrate an embodiment of a valve in perspective view.
  • FIGS. 2A-2B illustrate another embodiment of a valve in perspective view.
  • FIGS. 3A and 3B illustrate another embodiment of a valve in perspective view.
  • FIGS. 4A and 4B illustrate another embodiment of a valve in perspective view.
  • FIG. 5 illustrates an embodiment of a system that includes a valve.
  • FIG. 6 illustrates an embodiment of a system that includes a valve.
  • FIG. 7 illustrates an embodiment of a system that includes a valve.
  • DETAILED DESCRIPTION
  • Embodiments of the present invention are directed to an apparatus, system, and method for cardiac valve replacement and/or augmentation. For example, the apparatus can include a cardiac valve that can be used to replace an incompetent valve in a body lumen. Embodiments of the cardiac valve can include a support frame and cover that can be implanted through minimally-invasive techniques into a body lumen, such as an artery or a vein. In one example, embodiments of the present invention may help to augment or replace the function of a cardiac valve of individuals having heart valve disease.
  • The Figures herein follow a numbering convention in which the first digit or digits correspond to the drawing Figure number and the remaining digits identify an element or component in the drawing. Similar elements or components between different Figures may be identified by the use of similar digits. For example, 110 may reference element “10” in FIG. 1, and a similar element may be referenced as 210 in FIG. 2. As will be appreciated, elements shown in the various embodiments herein can be added, exchanged, and/or eliminated so as to provide any number of additional embodiments of valve.
  • Various embodiments of the invention are illustrated in the figures. Generally, the cardiac valve can be implanted within the fluid passageway of a body lumen, such as for replacement of a cardiac valve structure within the body lumen (e.g., an aortic valve at the aortic root), to regulate the flow of a bodily fluid through the body lumen in a single direction.
  • FIGS. 1A and 1B illustrate one embodiment of a cardiac valve 100. FIGS. 1A and 1B provide a perspective illustration of valve 100 in an open configuration (FIG. 1A) and a closed configuration (FIG. 1B). FIGS. 1C and 1D provide a sectional view of FIGS. 1A and 1B, respectively, to more clearly illustrate the embodiment of the cardiac valve 100.
  • Cardiac valve 100 includes a support frame 102 and a cover 104. The support frame 102 includes an outer surface 106 and an inner surface 108. The support frame 102 further includes a first end member 110 and a second end member 112 opposing the first end member 110. In one embodiment, the first end member 110 and the second end member 112 are in a substantially fixed distance relationship 114. As used herein, a substantially fixed distance relationship 114 indicates a fixed distance between the members 110 and 112 that may include variations of the fixed distance relationship inherently resulting from the manufacture of the articles of the present invention. In addition, the substantially fixed distance relationship 114 need not be consistent around the circumference of the cardiac valve 100. For example, the substantially fixed distance relationship 114 can be varied up to a predetermined percentage of an average valve diameter of the substantially fixed distance relationship 114. In one embodiment, the predetermined percentage can be up to seventy (70) percent (%).
  • The support frame 102 further includes an open frame configuration in which the first end member 110 and the second end member 112 are closed rings that define a sequence of convex curves 116 and concave curves 118. In one embodiment, the sequence of convex curves 116 and concave curves 118 are arranged such that the first end member 110 and the second end member 112 provide mirror images of each other set apart by the substantially fixed distance relationship 114. In another embodiment, the sequence of convex curves 116 and concave curves 118 are arranged such that the first end member 110 and the second end member 112 are substantially parallel. In an alternative embodiment, the sequence of convex curves 116 and concave curves 118 are arranged such that the relative position of the first end member 110 and the second end member 112 can have a variation from about zero (0) percent to about two hundred (200) percent variation as compared to an average distance or a preselected distance between the members 110 and 112. In one embodiment, the valve can be about twenty (20) to eighty (80) percent. As will be appreciated, the selection of these percentage values can be based on the anatomical location into which the valve is to be placed. As illustrated in FIGS. 1A and 1B, the sequence of convex curves 116 and concave curves 118 of the first and second end members 110 and 112 can transition between each other with a uniform radius of curvature for each of the convex curves 116 and concave curves 118. Alternatively, the sequence of convex curves 116 and concave curves 118 transition between each other in a non-uniform manner. For example, the convex curves 116 can have a radius of curvature that is different (e.g., smaller) than the radius of curvature for the concave curves 118 (FIGS. 2A and 2B). Further, the shape and relationship of the convex curves 116 and concave curves 118 for each of the first end member 110 and the second end member 112 need not be symmetrical relative to each other, rather they may provide for a non-symmetrical relationship, which may vary around the circumference.
  • The support frame 102 can further include cross-members 120 coupled to the first end member 110 and the second end member 112. In one embodiment, cross-members 120 help to maintain the first end member 110 and the second end member 112 in the substantially fixed distance relationship 114. In one embodiment, the cross-members 120 can include a cross-sectional shape and can be formed from the same or similar materials as the end members 110 and 112, as discussed herein. In addition, the cross-members 120 can include any number of configurations, including linear configurations in which cross member 120 are arranged in parallel relative to other cross-members 120. Other configurations include, but are not limited to, curved configurations, configurations including one or more bends in the cross member 120, and configurations that include coil configurations. Other configurations are also possible. In addition, the cross-members 120 can further include additional members spanning between the cross-members 120 and/or the end members 110 and 112, as will be discussed herein.
  • The support frame 102 can be formed from a wide variety of materials and in a wide variety of configurations. Generally, support frame 102 can have a unitary structure with an open frame configuration. For example, the open frame configuration can include frame members (e.g., first end member 110 and a second end member 112, cross-members 120) that define openings 124 through the support frame 102. The support frame 102 can also be self-expanding. Examples of self-expanding frames include those formed from temperature-sensitive memory alloy which changes shape at a designated temperature or temperature range. Alternatively, the self-expanding frames can include those having a spring-bias. In addition, the support frame 102 can have a configuration that allows the frame 102 to be radially expandable through the use of a balloon catheter.
  • While the support frame 102 illustrated herein is shown having a circular configuration, other configurations are also possible. For example, the support frame 102 can also include an elliptical configuration, or other configurations that can accommodate the physiological structure in which the support frame 102 is to be placed. In addition, the support frame 102 is illustrated as having linear or long curved members, it will be appreciated that the support frame 102 and/or the crossmembers 120 can have a configuration that allows the support frame 102 and/or the cross-members 120 to be flexible. Examples of such configurations include those that are zigzag and/or serpentine so as to allow the frame to be radially compressible. As such, the present invention should not be limited to the illustration of the support frame 102.
  • The support frame 102 can also provide sufficient contact and expansion force with the surface of a body lumen wall to encourage fixation of the valve 100 and to prevent retrograde flow within the body lumen. Anchoring elements (e.g., barbs) can also be included with valve 100, as will be discussed herein.
  • The members (e.g., first end member 110 and a second end member 112, cross-members 120) forming support frame 102 can include a variety of cross-sectional shapes and dimensions. For example, cross-sectional shapes for the members 122 can include, but are not limited to, circular, tubular, I-shaped, T-shaped, oval, and triangular. The members can also have a single cross-sectional shape (e.g., all members of support frame 102 can have a circular cross-sectional shape). In an additional embodiment, the members of the support frame 102 can include two or more cross-sectional shapes (e.g., a first cross-sectional shape for both the first end member 110 and a second end member 112, and a second cross-sectional shape for the cross-members 120).
  • The support frame 102 can be formed from any number of materials. For example, the support frame 102 can be formed from a biocompatible metal, metal alloy, polymeric material, or combination thereof. As discussed herein, the support frame 102 can be self-expanding or balloon expandable. Examples of suitable materials for the support frame 102 include, but are not limited to, medical grade stainless steel (e.g., 316L), titanium, tantalum, platinum alloys, niobium alloys, cobalt alloys, alginate, or combinations thereof. In an additional embodiment, the support frame 102 may be formed from a shape-memory material, such as shape memory plastics, polymers, and thermoplastic materials which are inert in the body. Shaped memory alloys having superelastic properties generally made from specific ratios of nickel and titanium, commonly known as nitinol, are also possible materials. Other materials are also possible.
  • Members (e.g., first end member 110 and a second end member 112, cross members 120) of the support frame 102 can be shaped and joined in any number of ways. For example, a single contiguous member can be bent around an elongate tubular mandrel to form the end members 110 and 112 of the support frame 102. The free ends of the single contiguous member can then be welded, fused, crimped, or otherwise joined together to form the support frame 102. In an additional embodiment, the cross-members 120 can be joined to the end members 110 and 112 in a similar manner. Alternatively, the support frame 102 can be derived (e.g., laser cut, water cut) from a single tubular segment. The support frame 102 can be heat set by a method as is typically known for the material which forms the support frame 102.
  • Support frame 102 and cover 104 can be expanded to provide lumen 126 having any number of sizes. For example, the size of lumen 126 can be determined based upon the type of body lumen and the body lumen size in which the valve 100 is to be placed. In an additional example, there can also be a minimum value for the width 128 for the support frame 102 that ensures that the support frame 102 will have an appropriate expansion force against the inner wall of the body lumen in which the valve 100 is being placed. The support frame 102 can also include a longitudinal length 130.
  • In one embodiment, the support frame 102 can further include one or more anchoring elements. For example, the one or more anchoring elements can include, but are not limited to, one or more barbs 132 projecting from the outer surface 106 of the support frame 102. The valve 100 can further include one or more radiopaque markers (e.g., tabs, sleeves, welds). For example, one or more portions of the valve frame 102 can be formed from a radiopaque material. Radiopaque markers can be attached to and/or coated onto one or more locations along the support frame 102. Examples of radiopaque material include, but are not limited to, gold, tantalum, and platinum. The position of the one or more radiopaque markers can be selected so as to provide information on the position, location and orientation of the valve 100 during its implantation.
  • As discussed herein, the cover 104 of the cardiac valve 100 forms valve leaflets 133 having surfaces defining a reversibly sealable opening 134 for unidirectional flow of a liquid through the valve 100. For example, the cover 104 can extend across an area between the convex curves 116 and the concave curves 118 of the second end member 112 to form valve leaflets 133 of the cardiac valve 100. The position and number of the convex and concave curves 116 and 118 in the second end member 112 determine the number of valve leaflets 133 of the cardiac valve 100.
  • For example, FIGS. 1A and 1B provide a bi-leaflet cardiac valve according to an embodiment of the present invention. As illustrated in FIGS. 1A and 1B, cover 104 extends across the area between a first convex curve 136 and a second convex curve 138 and down to the concave curves 118 of the second end member 112 to form a first valve leaflet 140 and a second valve leaflet 142.
  • In one embodiment, the first convex curve 136 and the second convex curve 138 of the second end member 112 are positioned opposite each other along a common axis 144. In this example, the common axis 144 bisects support frame 102 into symmetrical portions. As a result, the first valve leaflet 140 and the second valve leaflet 142 each display substantially the same shape, size and configuration as each other. In an alternative embodiment, the first convex curve 136 and the second convex curve 138 can be positioned so that the common axis 144 divides the support frame 102 into non-symmetrical portions. In this embodiment, the first valve leaflet 140 and the second valve leaflet 142 can have different shapes, sizes and configurations relative to each other.
  • In an additional embodiment, the cover 104 also extends over the first end member 110. In contrast to the second end member 112, however, the cover 104 terminates along the convex and concave curves 116 and 118 of the first end member 110 so as to define an open area 146 between the sequence of convex curves 116 and concave curves 118. As will be more fully discussed below, providing the open area 146 allows the valve 100 to accommodate the anatomical structures of the autologous valve being replaced so as to reduce any potential interference with anatomical structures adjacent the autologous valve (e.g., the coronary ostia located adjacent aortic valve).
  • Although the embodiments in FIGS. 1A-1D illustrate and describe a bileaflet configuration for the valve 100 of the present invention, designs employing a different number of valve leaflets are possible. For example, the second end member 112 can include additional convex curves 116 and the concave curves 118 so as to provide support structures for additional valve leaflets 133 (e.g., a tri-leaflet valve).
  • The cover 104 in conjunction with the support frame 102 defines the lumen 126 of the cardiac valve 100 for passing fluid (e.g., blood) there-through. The cover 104 further includes surfaces defining a reversibly sealable opening 134 for unidirectional flow of a liquid through the lumen 126. For example, a portion of the first valve leaflet 140 and the second valve leaflet 142 can join to form the reversibly sealable opening 134 for unidirectional flow of a liquid through the cardiac valve 100. FIGS. 1A and 1B illustrate embodiments in which the surfaces of the cover 104 can be deflectable between a closed configuration (FIG. 1B) in which fluid flow through the lumen 126 can be restricted and an open configuration (FIG. 1A) in which fluid flow through the lumen 126 can be permitted.
  • The first valve leaflet 140 and the second valve leaflet 142 can move relative the support frame 102 (i.e., the first valve leaflet 140 and the second valve leaflet 142 are attached to and pivot along the support frame 102). In one embodiment, the cover 104 provides sufficient excess material spanning support frame 102 to allow the first valve leaflet 140 and the second valve leaflet 142 to join sealing surfaces 148 at the reversibly sealable opening 134. The reversibly sealable opening 134 formed by the first and second valve leaflets 140 and 142 opens and closes in response to the fluid pressure differential across the valve leaflets 140 and 142. That is, antegrade blood flow causes the valve leaflets to open, thereby providing for unidirectional blood flow through the reversibly sealable opening. In contrast, retrograde blood flow causes the valve leaflets close, thereby preventing blood flow from passing through the reversibly sealable opening.
  • The first valve leaflet 140 and the second valve leaflet 142 further include arcuate edges 150 and 152 that are positioned adjacent each other along a substantially catenary curve between the first convex curve 136 and the second convex curve 138 of the second end member 112 in the closed configuration (FIG. 1B) of valve 100. Similarly, arcuate edges 150 and 152 can form the reversibly sealable opening 134 when the valve 100 is in the open configuration (FIG. 1A).
  • For example, under antegrade fluid flow (i.e., positive fluid pressure) moving from the first end member 110 towards the second end member 112 of the valve 100, the first and second valve leaflets 140 and 142 can expand toward the support frame 102 to create an opening through which fluid is permitted to move. In one embodiment, the first valve leaflet 140 and the second valve leaflet 142 can each expand to form a semi-tubular structure when fluid opens the reversibly sealable opening 134. In an additional embodiment, arcuate edge 150 and 152 of valve 100 can open to approximately the full inner diameter of a body lumen. An example of the open configuration for the valve is shown in FIG. 1A. Also as can be seen, the first and second valve leaflets 133 extend a variable distance beyond the second end member 112.
  • Under a retrograde fluid flow (i.e., negative fluid pressure) moving from the second end member 112 towards the first end member 110, the first and second valve leaflets 140 and 142 move away from the support frame 102 as the valve leaflets 140 and 142 begin to close. In one embodiment, the valve leaflets 140 and 142 include a predefined shape that allows for the retrograde fluid flow to develop pressure on a major surface 154 of the first and second valve leaflets 140 and 142.
  • For example, the major surface 154 can have a concave shape 156 to better collect retrograde fluid flow to urge the first valve leaflet 140 and the second valve leaflet 142 towards the closed configuration. As fluid pressure builds, the first and second valve leaflets 140 and 142 move towards each other eventually forming the reversibly sealable opening 134 (i.e., closing the valve 100), thereby restricting retrograde fluid flow through the valve 100. As can be seen in FIGS. 1B and 1D, when the valve leaflets 140, 142 obstruct the lumen 126 of the valve, the valve leaflets 140, 142 do not extend a variable distance beyond the second end member 112. Also, the valve leaflets 140, 142 are substantially perpendicular to the longitudinal axis of the valve.
  • In an additional embodiment, the first valve leaflet 140 and the second valve leaflet 142 can include one or more support structures, where the support structures can be integrated into and/or onto the valve leaflets 140 and 142. For example, the first valve leaflet 140 and the second valve leaflet 142 can include one or more support ribs having a predetermined shape. In one embodiment, the predetermined shape of the support ribs can include a curved bias so as to provide the first valve leaflet 140 and the second valve leaflet 142 with a curved configuration. Support ribs can be constructed of a flexible material and have dimensions (e.g., thickness, width and length) and cross-sectional shape that allows the support ribs to be flexible when the first valve leaflet 140 and the second valve leaflet 142 are urged into an open position upon experiencing sufficient blood flow pressure from the direction upstream from the valve, e.g., antegrade blood flow, and stiff when the first valve leaflet 140 and the second valve leaflet 142 are urged into a closed position upon experiencing sufficient back flow pressure from the direction downstream from the valve, e.g., retrograde blood flow. In an additional embodiment, support ribs can also be attached to support frame 102 so as to impart a spring bias to the valve leaflets 133 in either the open or the closed configuration.
  • In one embodiment, cover 104 used to form the valve leaflets 140 and 142 can be constructed of a material sufficiently thin and pliable so as to permit radially-collapsing of the valve leaflets for delivery by catheter to a location within a body lumen. The cover 104 can be constructed of a biocompatible material that can be either synthetic or biologic or a combination of synthetic and biologic biocompatible material. Possible synthetic materials include, but are not limited to, expanded polytetrafluoroethylene (ePTFE), polytetrafluoroethylene (PTFE), polystyrene-polyisobutylene-polystyrene (SIBS), polyurethane, segmented poly(carbonate-urethane), polyester, polyethlylene (PE), polyethylene terephthalate (PET), silk, urethane, Rayon, Silicone, or the like. In an additional embodiment, the synthetic material can also include metals, such as stainless steel (e.g., 316L) and nitinol. These synthetic materials can be in a woven, a knit, a cast or other known physical fluid-impermeable or permeable configurations.
  • Possible biologic materials include, but are not limited to, autologous, allogeneic or xenograft material. These include explanted veins, pericardium, facia lata, harvested cardiac valves, bladder, vein wall, various collagen types, elastin, intestinal submucosa, and decellularized basement membrane materials, such as small intestine submucosa (515), amniotic tissue, or umbilical vein.
  • As discussed herein, the cover 104 can be located over at least the outer surface 106 of the support frame 102. FIGS. 1A-1D provide one illustration of this embodiment. As can be seen, the leaflets 133 extend from the portion of the cover extending over the support frame 102. In an additional embodiment, the cover 104 can be located over at least the inner surface 108 of the support frame 102.
  • FIGS. 2A-2B provide a cross-sectional perspective view of cover 204 extending over both an inner surface 208 and the outer surface 206 of the support frame 202 to form the bi-leaflet cardiac valve. In one example, the cover 204 can further be located over the openings 224 defined by the members of the support frame 202. The cover 204 can also be joined to itself through the openings 224 so as to fully or partially encase the support frame 202.
  • Numerous techniques may be employed to laminate or bond the cover 204 on the outer surface 206 and/or the inner surface 208 of the support frame 202, including heat setting, adhesive welding, interlocking, application of uniform force and other bonding techniques. Additionally, the cover 204 may be folded over the first end member 210 of the support frame 202 to provide the cover 204 on both the outer surface 206 and the inner surface 208. Cover 204 can also be joined to itself and/or the members according to the methods described in U.S. Patent Application Publication US 2002/0178570 to Sogard et al.
  • The valve 200 can further include a layer of material 258 positioned between the cover 204 extending over the inner surface 208 and the outer surface 206 of the support frame 202. The layer of material 258 can be formed from the biocompatible material used for the cover 204. The layer of material 258, however, can be structurally different than the material of cover 204. For example, cover 204 can include a fluid permeable open woven, or knit, physical configuration to allow for tissue in-growth and stabilization, whereas the layer of material 258 can have a fluid impermeable physical configuration. Examples of the material 258 include, but are not limited to, the synthetic materials described herein. Other combinations of physical configurations for the cover 204 and the layer of material 258 are also possible.
  • Referring again to FIGS. 1A-1D, the support frame 102 and/or the cover 104, including the valve leaflets 140 and 142, may also be treated and/or coated with any number of surface or material treatments. For example, suitable bioactive agents which may be incorporated with or utilized together with the present invention may be selected from silver antimicrobial agents, metallic antimicrobial materials, growth factors, cellular migration agents, cellular proliferation agents, anti-coagulant substances, stenosis inhibitors, thrombo-resistant agents, antibiotic agents, anti-tumor agents, anti-proliferative agents, growth hormones, antiviral agents, anti-angiogenic agents, angiogenic agents, cholesterol-lowering agents, vasodilating agents, agents that interfere with endogenous vasoactive mechanisms, hormones, their homologs, derivatives, fragments, pharmaceutical salts and combinations thereof.
  • In the various embodiments of the present invention, the most useful bioactive agents can include those that modulate thrombosis, those that encourage cellular ingrowth, throughgrowth, and endothelialization, those that resist infection, and those that reduce calcification. For example, coating treatments can include one or more biologically active compounds and/or materials that may promote and/or inhibit endothelial, smooth muscle, fibroblast, and/or other cellular growth onto or into the support frame 102 and/or the cover 104, including the valve leaflets 140 and 142. Examples of such coatings include, but are not limited to, polyglactic acid, poly-L-lactic acid, glycol-compounds, and lipid compounds. Additionally, coatings can include medications, genetic agents, chemical agents, and/or other materials and additives. In addition, in embodiments having tubular members such as the tubular member 482 illustrated in FIGS. 4A-4B, agents that limit or decrease cellular proliferation can be useful. Similarly, the support frame 102 and/or the cover 104 may be seeded and covered with cultured tissue cells (e.g., endothelial cells) derived from a either a donor or the host patient which are attached to the valve leaflets 140 and 142. The cultured tissue cells may be initially positioned to extend either partially or fully over the valve leaflets 140 and 142.
  • Cover 104, in addition to forming valve leaflets 140 and 142, can also be capable of inhibiting thrombus formation, as discussed herein. Additionally, cover 104 may either prevent or facilitate tissue ingrowth there-through, as the particular application for the valve 100 may dictate. For example, cover 104 on the outer surface 106 may be formed from a porous material to facilitate tissue ingrowth there-through, while cover 104 on the inner surface 108 maybe formed from a material or a treated material which inhibits tissue ingrowth.
  • Cells can be associated with the present invention. For example, cells that have been genetically engineered to deliver bioactive proteins, such as the growth factors or antibodies mentioned herein, to the implant site can be associated with the present invention. Cells can be of human origin (autologous or allogenic) or from an animal source (xenogenic). Cells can be pre-treated with medication or preprocessed such as by sorting or encapsulation. The delivery media can be formulated as needed to maintain cell function and viability.
  • Thrombo-resistant agents associated with the valve may be selected from, but not limited to, heparin, heparin sulfate, hirudin, hyaluronic acid, chondroitin sulfate, dermatan sulfate, keratin sulfate, PPack (detropyenylalanine praline arginine chloromethylketone), lytic agents, including urokinase and streptokinase, their homologs, analogs, fragments, derivatives and pharmaceutical salts thereof.
  • Anti-coagulants can include, but are not limited to, D-Phe-Pro-Arg chloromethyl ketone, an RGD peptide-containing compound, heparain, antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors, tick antiplatelet peptides and combinations thereof.
  • Antibiotic agents can include, but are not limited to, penicillins, cephalosportins, vancomycins, aminoglycosides, quinolonges, polymyxins, erythromycins, tetracyclines, chloraphenicols, clindamycins, lincomycins, sulfonamides, their homologs, analogs, derivatives, pharmaceutical salts and combinations thereof.
  • Anti-proliferative agents for use in the present invention can include, but are not limited to, the following: paclitaxel, sirolimus, everolimus, or monoclonal antibodies capable of blocking smooth muscle cell proliferation, related compounds, derivatives, and combinations thereof.
  • Vascular cell growth inhibitors can include, but are not limited to, growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of a an antibody and a cytotoxin.
  • Vascular cell growth promoters include, but are not limited to, transcriptional activators and transcriptional promoters. Anti-inflammatory agents can include, but are not limited to, dexametbasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazinemesalamne, and combinations thereof.
  • FIGS. 3A and 3B illustrate an additional embodiment of a cardiac valve 300. FIGS. 3A and 3B provide a perspective illustration of valve 300 having three valve leaflets 333 in an open configuration (FIG. 3A) and a closed configuration (FIG. 3B).
  • As discussed herein, cardiac valve 300 includes the support frame 302 having the first end member 310 and the second end member 312 opposing the first end member 310 in the substantially fixed distance relationship 314. In the present example, the cover 304 of the cardiac valve 300 forms a tri-leaflet valve having surfaces defining the reversibly sealable opening 334 for unidirectional flow of a liquid through the valve 300. As illustrated, FIGS. 3A and 3B provide a tri-leaflet cardiac valve in which cover 304 extends across the area between the first convex curve 336, the second convex curve 338, and a third convex curve 364, and down to the concave curves 318 of the second end member 312 to form the first valve leaflet 340, the second valve leaflet 342, and a third valve leaflet 366
  • In one embodiment, the convex curves 336, 338, and 364 can lay on a common plane 368, as illustrated in FIGS. 3A and 3B. However, the convex curves 336, 338, and 364 can lay need not all lay on the common plane 368. It is possible that one or more of the convex curves 336, 338, and 364 can lie above and/or below the common plane 368. In addition, the convex curves 336, 338, and 364 can be positioned at equal distances around the second end member 312. As a result, the valve leaflets 336, 338, and 364 each display substantially the same shape, size and configuration as each other. In an alternative embodiment, the convex curves 336, 338, and 364 can be positioned at one or more unequal distances around the second end member 312. In this embodiment, the valve leaflets 336, 338, and 364 can each have different shapes, sizes and configurations relative to each other.
  • The cover 304 in conjunction with the support frame 302 defines the lumen 326 of the cardiac valve 300 for passing fluid (e.g., blood) there-through. The cover 304 can further include surfaces defining the reversibly sealable opening 334 for unidirectional flow of a liquid through the lumen 326. For example, a portion of the first valve leaflet 340, the second valve leaflet 342, and the third valve leaflet 366 can join to form the reversibly sealable opening 334 for unidirectional flow of a liquid through the cardiac valve 300. FIGS. 3A and 3B illustrate embodiments in which the valve leaflets 340, 342, and 366 can deflect between a closed configuration (FIG. 3B) in which fluid flow through the lumen 326 can be restricted and an open configuration (FIG. 3A) in which fluid flow through the lumen 326 can be permitted.
  • The first valve leaflet 340, the second valve leaflet 342, and the third valve leaflet 366 can move relative the support frame 302 between the open configuration and the closed configuration. As discussed, the cover 304 provides sufficient excess material spanning support frame 302 to allow the valve leaflets 340, 342, and 366 to join sealing surfaces 348 at a reversibly sealable opening 334. The reversibly sealable opening 334 formed by the first, second, and third valve leaflets 340, 342, and 366 opens and closes in response to the fluid pressure differential across the valve leaflets.
  • The valve leaflets 340, 342, and 366 each include concave surfaces 370 projecting from the support frame 302 towards an arcuate edge 372 projecting into the lumen 326. As discussed, the valve leaflets 340, 342, and 366 can have approximately the same size and shape. The arcuate edge 372 of the valve leaflets 340, 342, and 366 can each further include a nodular interruption 374 at approximately the center 376 of the arcuate edge 372 to allow the edges of the leaflets 340, 342, and 366 to properly meet as the valve closes.
  • During retrograde flow (i.e., negative fluid pressure), the valve leaflets 340, 342, and 366 can fall into the lumen to close the reversibly sealable opening 334 and support the column of fluid (e.g., blood). During antegrade fluid flow (i.e., positive fluid pressure) the valve leaflets 340, 342, and 366 can expand or move toward the support frame 302 to create an opening through which fluid is permitted to move. In one embodiment, the valve leaflets 340, 342, and 366 can each expand or move to form a semi-tubular structure when fluid opens the reversibly sealable opening 334. In an additional embodiment, the valve leaflets 340, 342, and 366 can include one or more support structures (e.g., support ribs), as discussed herein.
  • Cover 304 can extend over at least the outer surface 306 of the support frame 302 to form the valve leaflets of the tri-leaflet cardiac valve. Alternatively, cover 304 can also be located over at least the inner surface 308 of the support frame 302 to form the valve leaflets of the tri-leaflet cardiac valve. The cover 304 can be joined to the support frame 302 and itself as discussed herein. In addition, the valve 300 can further include a layer of material 358 positioned between the cover 304 extending over the inner surface 308 and the outer surface 306 of the support frame 302. The cover 304, including the valve leaflets 340, 342, and 366, may also be treated and/or coated with any number of surface or material treatments, as discussed herein.
  • FIGS. 4A and 4B illustrate a further embodiment of a cardiac valve 400. FIGS. 4A and 4B provide a perspective illustration of valve 400 in an open configuration (FIG. 4A) and a closed configuration (FIG. 4B). As discussed herein, the valve 400 the support frame 402 and the cover 404 that forms valve leaflets having surfaces defining a reversibly sealable opening 434 for unidirectional flow of a liquid through the valve 400.
  • In addition, the present embodiment further includes an elongate tubular member 482 having a first end 484 and a second end 486. As illustrated, the elongate tubular member 482 can be positioned relative the support frame 402 to allow the first end 484 of the member 482 to be on a first side of the valve leaflets and the second end 486 on a second side of the valve leaflets. In one embodiment, the tubular member 482 can pass through an opening in a valve leaflet, where the tubular member 482 and the valve leaflet form a fluid tight seal. Alternatively, the tubular member 482 passes through a region of the reversibly sealable opening 434, where the leaflets seal around the tubular member 482 when they are in their closed position. As illustrated in FIGS. 4A and 4B, the tubular member 482 can be positioned within the opening defined by the support frame 402. In an alternative embodiment, the tubular member 482 can be positioned outside of the support frame 402.
  • The tubular member 482 can allow fluid communication across the valve 400 when the valve leaflet 433 are in their closed position. In one embodiment, the tubular member 482 can allow for blood at an arterial pressure to be supplied from a region distal to the valve 400 to vessels located proximal the valve 400. In one embodiment, the tubular member 482 can allow the valve 400 to be positioned at a more convenient and/or less-diseased location in the vasculature (e.g., the aorta) while still allowing blood at arterial pressure to be supplied to the appropriate coronary arteries (e.g., via the coronary ostium).
  • The tubular member 482 can include any number of physical configurations. For example, as shown in FIG. 4A, the tubular member 482 can include a predetermined length and a predetermined bend 483 to allow the second end 486 of the tubular member 482 to be implanted in a desired location. Examples of such locations include, but are not limited to, a coronary ostium. The predetermined length of the tubular member 482 can be in a range from 10 mm to 50 mm, where the length of the tubular member 482 will be determined based on where the valve 400 is being implanted along with the patient's individual physiological parameters and measurements.
  • As will be appreciated, the valve 400 can include more than one tubular member 482. For example, the valve 400 can include two or more tubular members 482, each tubular member supplying a coronary artery of the patient's vasculature. In addition, each of the tubular members 482 can have similar or distinct physical characteristics (e.g., length, inner/outer diameter, predetermined shape). In one embodiment, each of the tubular members 482 can further include one or more radiopaque marks to allow each tubular member 482 to be uniquely identified.
  • The tubular member 482 can further include a predetermined shape. In one embodiment, the predetermined shape can be determined by the anatomical location in which the valve 400 is being placed along with the anatomical location in which the second end 486 of the tubular member 482 is to be placed. As illustrated in FIGS. 4A and 4B, the tubular member 482 can include combinations of linear and bend portions imparted into the tubular member 484 (e.g., the predetermined bend 483 illustrated in FIG. 4B.).
  • The tubular member 482 can be constructed of a material having sufficient flexibility so as to permit the second end 486 of the tubular member 482 to remain positioned in its proper anatomical location within the patient, while also being flexible enough to allow the first end 484 to move radially with the valve leaflet. The tubular member 482 can be constructed of a biocompatible material that can be either synthetic or biologic. Examples of these materials include those discussed herein for the cover 404. In addition, the material used in the construction of the tubular member 484 can be the same or a different material used for the construction of the cover 404. The tubular member 482 can also include a stent support structure to help maintain a predetermined shape of the tubular member 482.
  • The tubular member 482 further includes an inner diameter 488 and outer diameter 490. The inner diameter 488 can be in a range of 2.0 mm to 5.5 mm. Alternatively, the inner diameter 488 can be in a range of 3.0 mm to 4.5 mm. In one embodiment, the dimension of the inner diameter 488 will typically be a function of the volume of fluid flow that is desired to move through the tubular member 484. The dimension for the outer diameter 490 will be dependent upon the wall thickness of the tubular member 482 required to provide proper flexibility and rigidity to maintain its position once placed in the patient.
  • The embodiments of the valve of the present invention can be formed in any number of ways. For example, a support frame and a cover are both provided for forming the cardiac valve. In the present example, the cover can have a cylindrical shape of essentially uniform inner diameter, where the inner diameter of the cover is approximately the same size as an outer diameter of the support frame.
  • The cover can be positioned over the outer surface of the support frame. For example, the cover can be stretched slightly to allow the support frame to be placed within the cover. Alternatively, the outer diameter of the tubular frame could be enlarged so as to place the cover around the outer surface of the support frame. Other ways of placing the cover around the outer surface of the support frame are also possible, including placing the cover around both the inside and the outside of the frame.
  • In one embodiment, the cover can be positioned over and attached to the support frame so that the cover extends between the convex curves of the second end member to form the valve leaflets. For example, the support frame includes the first convex curve and the second convex curve along the second end member. Providing cover over the support frame then forms the first valve leaflet and the second valve leaflet of the cardiac valve.
  • As discussed herein, the cover can also be trimmed along the first end member so as to define the open area between the sequence of convex curves and concave curves along the first end member. Alternatively, the cover can include a first end having a series of convex and concave curves that correspond to those of the first end member so as to provide the open area.
  • In an additional embodiment, the cardiac valve can be formed by providing support frame and cover, where the second end member of support frame includes the first convex curve, the second convex curve, and the third convex curve. Cover can include cylindrical shape that has a second end having a predetermined shape that allows for the formation of the valve leaflets of the tri-leaflet cardiac valve. The second end can also include arcuate edges each having the optional nodular interruption. The cover further includes concave surfaces, as described herein, which can be imparted into the cover through any number of manufacturing processes, including, but not limited to, thermo-molding, heat setting, and chemical cross-linking. As discussed herein, this example of the cover permits the valve leaflets to be created once the cover is properly positioned on the support frame.
  • As discussed herein, the cover can also be positioned over both the outer surface and the inner surface of the support frame. For example, two covers can be positioned on the support frame to provide an embodiment of the cardiac valve, or a longer cover can be used over the support frame. In addition, additional material can be positioned between the two covers at least in the area between the convex and concave curves of the second end member.
  • In addition, one or more flexible support ribs having a predetermined shape could also be incorporated into the cover in forming the concave surfaces. As discussed herein, the cover configuration having the arcuate edges, nodular interruptions, and the concave surfaces permits the valve leaflets to be created once the cover is properly positioned over the support frame. The cover can then be affixed to the support frame and itself as discussed herein.
  • The cover can also be trimmed along the first end member so as to define the open area between the sequence of convex curves and concave curves along the first end member. Alternatively, the first end of cover can include a series of convex and concave curves that correspond to those of the first end member so as to provide the open area.
  • In an additional embodiment, surfaces defining the opening through or around the cover can also be provided on the cardiac valve. The tubular member can then be coupled in fluid tight communication to the opening to provide fluid communication with the opening around or through the cover. In one embodiment, the first end of the tubular member can be coupled to the support frame with the opening and the lumen of the tubular member aligned so that fluid can move through the opening and the tubular member once the valve has been implanted in a patient. Alternatively, the tubular member can be positioned in the patient, independent of the valve and then subsequently coupled to the valve once the valve has been implanted in the patient.
  • As discussed herein, the tubular member allows for the valve to be positioned in any number of locations within the vasculature while still allowing fluid communication with adjacent physiological structures. For example, valve could be implanted in the aorta of a patient downstream of the coronary ostia. In order to provide sufficient blood supply to the coronary ostia, the tubular member can be positioned with the second end of the tubular member in the coronary ostia so as to supply arterial blood at arterial pressures to the coronary arteries.
  • FIG. 5 illustrates one embodiment of a system 509. System 509 includes valve 500, as described herein, reversibly joined to a delivery catheter 511. The delivery catheter 511 includes an elongate body 513 having a proximal end 515 and a distal end 517, where valve 500 can be located between the proximal end 515 and distal end 517. The delivery catheter 511 can further include a lumen 519 longitudinally extending to the distal end 517. In one embodiment, lumen 519 extends between proximal end 515 and distal end 517 of catheter 511. The catheter 511 can further include a guidewire lumen 521 that extends within the elongate body 513, were the guidewire lumen 521 can receive a guidewire for positioning the catheter 511 and the valve 500 within a body lumen (e.g., the aorta of a patient).
  • The system 509 can further include a deployment shaft 523 positioned within lumen 519, and a sheath 525 positioned adjacent the distal end 517. In one embodiment, the valve 500 can be positioned at least partially within the sheath 525 and adjacent the deployment shaft 523. The deployment shaft 523 can be moved within the lumen 519 to deploy valve 500. For example, deployment shaft 523 can be used to push valve 500 from sheath 525 in deploying valve 500.
  • FIG. 6 illustrates an additional embodiment of the system 609. The catheter 611 includes elongate body 613, lumen 619, a retraction system 627 and a retractable sheath 629. The retractable sheath 629 can be positioned over at least a portion of the elongate body 613, where the retractable sheath 629 can move longitudinally along the elongate body 613. The valve 600 can be positioned at least partially within the retractable sheath 629, where the retractable sheath 629 moves along the elongate body 613 to deploy the valve 600. In one embodiment, retraction system 627 includes one or more wires 699 coupled to the retractable sheath 627, where the wires 699 are positioned at least partially within and extend through lumen 619 in the elongate body 613. Wires 699 of the retraction system 627 can then be used to retract the retractable sheath 629 in deploying valve 600.
  • FIG. 7 illustrates an additional embodiment of the system 709. The catheter 711 includes elongate body 713, an inflatable balloon 731 positioned adjacent the distal end 717, and a lumen 735 longitudinally extending in the elongate body 713 of the catheter 711 from the inflatable balloon 731 to the distal end 717. In the present example, the inflatable balloon 731 can be at least partially positioned within the lumen 726 of the valve 700. The inflatable balloon 731 can be inflated through the lumen 735 to deploy the valve 700.
  • The embodiments of the present invention further include methods for forming the valve of the present invention, as discussed herein. For example, the valve can be formed from the support frame and the cover over at least the outer surface of the support frame, where the cover includes surfaces defining the reversibly sealable opening for unidirectional flow of a liquid through the lumen. In an additional example, the valve can be reversibly joined to the catheter, which can include a process of altering the shape of the valve from a first shape, for example an expanded state, to the compressed state, as described herein.
  • For example, the valve can be reversibly joined with the catheter by positioning valve in the compressed state at least partially within the sheath of the catheter. In one embodiment, positioning the valve at least partially within the sheath of the catheter includes positioning the valve in the compressed state adjacent the deployment shaft of the catheter. In another embodiment, the sheath of the catheter functions as a retractable sheath, where the valve in the compressed state can be reversibly joined with the catheter by positioning the valve at least partially within the reversible sheath of the catheter. In a further embodiment, the catheter can include an inflatable balloon, where the balloon can be positioned at least partially within the lumen of the valve, for example, in its compressed state.
  • The embodiments of the valve described herein may be used to replace, supplement, or augment valve structures within one or more lumens of the body. For example, embodiments of the present invention may be used to replace an incompetent cardiac valve of the heart, such as the aortic, pulmonary and/or mitral valves of the heart.
  • In one embodiment, the method of replacing, supplementing, and/or augmenting a valve structure can include positioning at least part of the catheter including the valve at a predetermined location within an artery of a patient, such as in the aorta adjacent the root of the aortic valve. In positioning the valve of the present invention within the aorta, particular physiological structures need to be taken into consideration. For example, the valve of the present invention works in conjunction with the coronary artery ostia much in the same way as the native aortic valve. This is accomplished due to the configuration of both the support frame and the cover of the valve as described herein.
  • For example, the configuration of the valve of the present invention permits the valve to be implanted such that the support frame can be positioned between the native aortic valve and the coronary artery ostia. As discussed herein, the open area defined by the support frame allows the valve to be seated adjacent the native aortic valve. In addition, the valve leaflets of the present invention can be in the same relative position as the native valve leaflets. This allows the valve leaflets of the present invention to interact with the coronary ostia positioned in the aortic sinuses (sinuses of Valsalva) adjacent the aortic valve in the similar manner as the native valve leaflets. So, the valve of the present invention can properly accommodate both the aortic valve and the coronary ostia.
  • In one embodiment, positioning the catheter including the valve within the body lumen includes introducing the catheter into the cardiovascular system of the patient using minimally invasive percutaneous, transluminal catheter based delivery system, as is known in the art. For example, a guidewire can be positioned within the cardiovascular system of a patient that includes the predetermined location. The catheter, including valve, as described herein, can be positioned over the guidewire and the catheter advanced so as to position the valve at or adjacent the predetermined location. In one embodiment, radiopaque markers on the catheter and/or the valve, as described herein, can be used to help locate and position the valve.
  • The valve can be deployed from the catheter at the predetermined location in any number of ways, as described herein. In one embodiment, valve of the present invention can be deployed and placed in any number of cardiovascular locations. For example, valve can be deployed and placed within a major artery of a patient. In one embodiment, major arteries include, but are not limited to, the aorta. In addition, valves of the present invention can be deployed and placed within other major arteries of the heart and/or within the heart itself, such as in the pulmonary artery for replacement and/or augmentation of the pulmonary valve and between the left atrium and the left ventricle for replacement and/or augmentation of the mitral valve. Other locations are also possible.
  • As discussed herein, the valve can be deployed from the catheter in any number of ways. For example, the catheter can include the retractable sheath in which valve can be at least partially housed, as discussed herein. Valve can be deployed by retracting the retractable sheath of the catheter, where the valve self-expands to be positioned at the predetermined location. In an additional example, the catheter can include a deployment shaft and sheath in which valve can be at least partially housed adjacent the deployment shaft, as discussed herein. Valve can be deployed by moving the deployment shaft through the catheter to deploy valve from the sheath, where the valve self-expands to be positioned at the predetermined location. In an additional embodiment, the valve can be deployed through the use of an inflatable balloon. In a further embodiment, the valve can partially self-expand upon retracting a sheath in which the valve is located, and then deployed through the use of an inflatable balloon.
  • Once implanted, the valve can provide sufficient contact and expansion force against the body lumen wall to prevent retrograde flow between the valve and the body lumen wall, and to securely located the valve and prevent migration of the valve. For example, the valve can be selected to have a larger expansion diameter than the diameter of the inner wall of the body lumen. This can then allow valve to exert a force on the body lumen wall and accommodate changes in the body lumen diameter, while maintaining the proper placement of valve. As described herein, the valve can engage the lumen so as to reduce the volume of retrograde flow through and around valve. It is, however, understood that some leaking or fluid flow may occur between the valve and the body lumen and/or through valve leaflets.
  • While the present invention has been shown and described in detail above, it will be clear to the person skilled in the art that changes and modifications may be made without departing from the spirit and scope of the invention. As such, that which is set forth in the foregoing description and accompanying drawings is offered by way of illustration only and not as a limitation. The actual scope of the invention is intended to be defined by the following claims, along with the full range of equivalents to which such claims are entitled.
  • In addition, one of ordinary skill in the art will appreciate upon reading and understanding this disclosure that other variations for the invention described herein can be included within the scope of the present invention. For example, the support frame 102 and/or the cover 104 can be coated with a non-thrombogenic biocompatible material, as are known or will be known. Other biologically active agents or cells may also be utilized.
  • In the foregoing Detailed Description, various features are grouped together in several embodiments for the purpose of streamlining the disclosure. This method of disclosure is not to be interpreted as reflecting an intention that the embodiments of the invention require more features than are expressly recited in each claim. Rather, as the following claims reflect, inventive subject matter lies in less than all features of a single disclosed embodiment. Thus, the following claims are hereby incorporated into the Detailed Description, with each claim standing on its own as a separate embodiment.

Claims (20)

What is claimed is:
1. A valve having an open valve configuration and a closed valve configuration, the valve comprising:
a support frame, the support frame having an outer surface and an inner surface defining a valve lumen, the support frame comprising a first frame end member defining a first frame end opening, and a second frame end member defining a second frame end opening, the first frame end member forming a first frame end, the second frame end member forming a second frame end; and
a cover attached to the outer surface of the support frame, the cover having a predetermined shape forming valve leaflets with an arcuate edge that forms a part of an end of the cover;
wherein when the valve is in the open valve configuration the arcuate edge of the valve leaflets extends a variable longitudinal distance beyond the second frame end member; and
wherein when the valve is in the closed valve configuration the arcuate edge of the valve leaflets does not extend a longitudinal distance beyond the second frame member so that the valve leaflets obstruct the second frame opening and the valve leaflets have a concave shape extending from the second frame end member to the arcuate edge, a portion of valve leaflets being positioned within the valve lumen.
2. The valve of claim 1, the valve leaflets extending radially inward from the second frame member when the valve leaflets obstruct the second frame end opening.
3. The valve of claim 1, the first and second frame end members comprising a plurality of convex curves and a plurality of concave curves.
4. The valve of claim 3, each valve leaflet extending between two adjacent convex curves of the second frame end member.
5. The valve of claim 4, the valve leaflets being two valve leaflets.
6. The valve of claim 5, the two valve leaflets having a same shape and size.
7. The valve of claim 4, the valve leaflets being three valve leaflets.
8. The valve of claim 7, the three valve leaflets having a same shape and size.
9. The valve of claim 8, wherein the arcuate edge of the valve leaflets includes a nodular interruption.
10. The valve of claim 3, wherein the first frame end member and the second frame end member are equidistant from one another and coupled to one another by cross-members.
11. The valve of claim 1, the first and second frame end members having a same shape.
12. The valve of claim 3, the cardiac valve having a first valve end, the first cover end attached to the first frame end member, the first cover end having a shape complementary to the plurality of convex curves and the plurality of concave curves of the first frame end member so that the first valve end has a plurality of convex curves and a plurality of concave curves.
13. The cardiac valve of claim 1, wherein the valve leaflets pivot along the second frame end member between the closed and open valve configurations.
14. A valve comprising leaflets having an open configuration and a closed configuration, the valve having a first longitudinal extent when the leaflets are in the open configuration and a second longitudinal extent when the leaflets are in the closed configuration, the second longitudinal extent less than the first longitudinal extent.
15. The valve of claim 14, further comprising a frame, wherein the first longitudinal extent is greater than a longitudinal extent of the frame.
16. The valve of claim 14, the valve having opposed valve ends, wherein only one of the opposed valve ends has convex and concave curves when the leaflets are in the open configuration and both of the opposed valve ends has convex and concave curves when the leaflets are in the closed configuration;
17. The valve of claim 16, wherein the convex and concave curves are defined by a frame.
18. A valve having first and second valve ends and a longitudinal valve length therebetween, the valve comprising:
a frame defining a lumen and having a longitudinal frame length, a first end of the frame forming the first valve end;
leaflets, each leaflets having first and second leaflet ends, the first leaflet end engaged to the frame, the second leaflet end being movable between an open and a closed position;
wherein the second leaflet end forms the second end of the valve when the second leaflet end is in the open position and the longitudinal valve length is greater than the longitudinal frame length.
19. The valve of claim 18, the frame comprising convex curves and concave curves at a first frame end and convex curves and concave curves at a second frame end.
20. The valve of claim 19, the first frame end defined by a first frame member and the second frame end defined by a second frame member equidistant from the first frame member.
US14/084,088 2004-09-02 2013-11-19 Cardiac Valve, System, and Method Abandoned US20140081390A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/084,088 US20140081390A1 (en) 2004-09-02 2013-11-19 Cardiac Valve, System, and Method
US14/556,960 US9918834B2 (en) 2004-09-02 2014-12-01 Cardiac valve, system and method

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/933,088 US7566343B2 (en) 2004-09-02 2004-09-02 Cardiac valve, system, and method
US12/508,369 US8002824B2 (en) 2004-09-02 2009-07-23 Cardiac valve, system, and method
US13/214,520 US8932349B2 (en) 2004-09-02 2011-08-22 Cardiac valve, system, and method
US14/084,088 US20140081390A1 (en) 2004-09-02 2013-11-19 Cardiac Valve, System, and Method

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/214,520 Continuation US8932349B2 (en) 2004-09-02 2011-08-22 Cardiac valve, system, and method

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/556,960 Continuation US9918834B2 (en) 2004-09-02 2014-12-01 Cardiac valve, system and method

Publications (1)

Publication Number Publication Date
US20140081390A1 true US20140081390A1 (en) 2014-03-20

Family

ID=35944415

Family Applications (5)

Application Number Title Priority Date Filing Date
US10/933,088 Active 2026-07-22 US7566343B2 (en) 2004-09-02 2004-09-02 Cardiac valve, system, and method
US12/508,369 Expired - Fee Related US8002824B2 (en) 2004-09-02 2009-07-23 Cardiac valve, system, and method
US13/214,520 Active 2024-09-14 US8932349B2 (en) 2004-09-02 2011-08-22 Cardiac valve, system, and method
US14/084,088 Abandoned US20140081390A1 (en) 2004-09-02 2013-11-19 Cardiac Valve, System, and Method
US14/556,960 Active 2024-10-28 US9918834B2 (en) 2004-09-02 2014-12-01 Cardiac valve, system and method

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US10/933,088 Active 2026-07-22 US7566343B2 (en) 2004-09-02 2004-09-02 Cardiac valve, system, and method
US12/508,369 Expired - Fee Related US8002824B2 (en) 2004-09-02 2009-07-23 Cardiac valve, system, and method
US13/214,520 Active 2024-09-14 US8932349B2 (en) 2004-09-02 2011-08-22 Cardiac valve, system, and method

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/556,960 Active 2024-10-28 US9918834B2 (en) 2004-09-02 2014-12-01 Cardiac valve, system and method

Country Status (5)

Country Link
US (5) US7566343B2 (en)
EP (2) EP1788984B1 (en)
AT (1) ATE545389T1 (en)
ES (1) ES2379180T3 (en)
WO (1) WO2006031469A1 (en)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004030568A2 (en) * 2002-10-01 2004-04-15 Ample Medical, Inc. Device and method for repairing a native heart valve leaflet
US6602286B1 (en) 2000-10-26 2003-08-05 Ernst Peter Strecker Implantable valve system
US8308797B2 (en) 2002-01-04 2012-11-13 Colibri Heart Valve, LLC Percutaneously implantable replacement heart valve device and method of making same
US6752828B2 (en) * 2002-04-03 2004-06-22 Scimed Life Systems, Inc. Artificial valve
US6945957B2 (en) 2002-12-30 2005-09-20 Scimed Life Systems, Inc. Valve treatment catheter and methods
US8128681B2 (en) 2003-12-19 2012-03-06 Boston Scientific Scimed, Inc. Venous valve apparatus, system, and method
US7854761B2 (en) 2003-12-19 2010-12-21 Boston Scientific Scimed, Inc. Methods for venous valve replacement with a catheter
US7566343B2 (en) 2004-09-02 2009-07-28 Boston Scientific Scimed, Inc. Cardiac valve, system, and method
DE102005003632A1 (en) 2005-01-20 2006-08-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Catheter for the transvascular implantation of heart valve prostheses
US20060173490A1 (en) 2005-02-01 2006-08-03 Boston Scientific Scimed, Inc. Filter system and method
US7854755B2 (en) 2005-02-01 2010-12-21 Boston Scientific Scimed, Inc. Vascular catheter, system, and method
US7670368B2 (en) 2005-02-07 2010-03-02 Boston Scientific Scimed, Inc. Venous valve apparatus, system, and method
US7780722B2 (en) * 2005-02-07 2010-08-24 Boston Scientific Scimed, Inc. Venous valve apparatus, system, and method
US7867274B2 (en) 2005-02-23 2011-01-11 Boston Scientific Scimed, Inc. Valve apparatus, system and method
US7722666B2 (en) 2005-04-15 2010-05-25 Boston Scientific Scimed, Inc. Valve apparatus, system and method
US7914569B2 (en) 2005-05-13 2011-03-29 Medtronics Corevalve Llc Heart valve prosthesis and methods of manufacture and use
US8012198B2 (en) 2005-06-10 2011-09-06 Boston Scientific Scimed, Inc. Venous valve, system, and method
US7569071B2 (en) 2005-09-21 2009-08-04 Boston Scientific Scimed, Inc. Venous valve, system, and method with sinus pocket
US7799038B2 (en) 2006-01-20 2010-09-21 Boston Scientific Scimed, Inc. Translumenal apparatus, system, and method
US8303648B2 (en) * 2006-04-25 2012-11-06 Cook Medical Technologies Llc Artificial venous valve containing therapeutic agent
WO2007127362A2 (en) * 2006-04-26 2007-11-08 The Cleveland Clinic Foundation Apparatus and method for treating cardiovascular diseases
US8652201B2 (en) * 2006-04-26 2014-02-18 The Cleveland Clinic Foundation Apparatus and method for treating cardiovascular diseases
WO2007130881A2 (en) * 2006-04-29 2007-11-15 Arbor Surgical Technologies, Inc. Multiple component prosthetic heart valve assemblies and apparatus and methods for delivering them
US20080126131A1 (en) * 2006-07-17 2008-05-29 Walgreen Co. Predictive Modeling And Risk Stratification Of A Medication Therapy Regimen
US11304800B2 (en) 2006-09-19 2022-04-19 Medtronic Ventor Technologies Ltd. Sinus-engaging valve fixation member
US8834564B2 (en) 2006-09-19 2014-09-16 Medtronic, Inc. Sinus-engaging valve fixation member
US8414643B2 (en) 2006-09-19 2013-04-09 Medtronic Ventor Technologies Ltd. Sinus-engaging valve fixation member
US8133270B2 (en) 2007-01-08 2012-03-13 California Institute Of Technology In-situ formation of a valve
JP5313928B2 (en) 2007-02-05 2013-10-09 ボストン サイエンティフィック リミテッド Percutaneous valves and systems
US8070802B2 (en) * 2007-02-23 2011-12-06 The Trustees Of The University Of Pennsylvania Mitral valve system
US7896915B2 (en) 2007-04-13 2011-03-01 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
US8828079B2 (en) 2007-07-26 2014-09-09 Boston Scientific Scimed, Inc. Circulatory valve, system and method
DE102007043830A1 (en) 2007-09-13 2009-04-02 Lozonschi, Lucian, Madison Heart valve stent
US20090138079A1 (en) * 2007-10-10 2009-05-28 Vector Technologies Ltd. Prosthetic heart valve for transfemoral delivery
US7846199B2 (en) * 2007-11-19 2010-12-07 Cook Incorporated Remodelable prosthetic valve
US7892276B2 (en) 2007-12-21 2011-02-22 Boston Scientific Scimed, Inc. Valve with delayed leaflet deployment
EP3572044B1 (en) 2008-01-24 2021-07-28 Medtronic, Inc. Stents for prosthetic heart valves
US8157853B2 (en) 2008-01-24 2012-04-17 Medtronic, Inc. Delivery systems and methods of implantation for prosthetic heart valves
BR112012021347A2 (en) 2008-02-26 2019-09-24 Jenavalve Tecnology Inc stent for positioning and anchoring a valve prosthesis at an implantation site in a patient's heart
US9044318B2 (en) 2008-02-26 2015-06-02 Jenavalve Technology Gmbh Stent for the positioning and anchoring of a valvular prosthesis
US8313525B2 (en) 2008-03-18 2012-11-20 Medtronic Ventor Technologies, Ltd. Valve suturing and implantation procedures
US8998981B2 (en) 2008-09-15 2015-04-07 Medtronic, Inc. Prosthetic heart valve having identifiers for aiding in radiographic positioning
CN102292053A (en) 2008-09-29 2011-12-21 卡迪尔克阀门技术公司 Heart valve
WO2010040009A1 (en) 2008-10-01 2010-04-08 Cardiaq Valve Technologies, Inc. Delivery system for vascular implant
US8137398B2 (en) 2008-10-13 2012-03-20 Medtronic Ventor Technologies Ltd Prosthetic valve having tapered tip when compressed for delivery
US20100152838A1 (en) * 2008-12-15 2010-06-17 Wei-Chang Kang Implantable Valvular Prosthesis
US20100174363A1 (en) * 2009-01-07 2010-07-08 Endovalve, Inc. One Piece Prosthetic Valve Support Structure and Related Assemblies
EP4119098A1 (en) 2009-04-15 2023-01-18 Edwards Lifesciences CardiAQ LLC Vascular implant and delivery system
AU2010328106A1 (en) 2009-12-08 2012-07-05 Avalon Medical Ltd. Device and system for transcatheter mitral valve replacement
AU2015230879B2 (en) * 2009-12-08 2017-06-15 Avalon Medical Ltd. Device and system for transcatheter mitral valve replacement
US9522062B2 (en) 2010-02-24 2016-12-20 Medtronic Ventor Technologies, Ltd. Mitral prosthesis and methods for implantation
US8361144B2 (en) 2010-03-01 2013-01-29 Colibri Heart Valve Llc Percutaneously deliverable heart valve and methods associated therewith
WO2011120050A1 (en) 2010-03-26 2011-09-29 Thubrikar Aortic Valve, Inc. Valve component, frame component and prosthetic valve device including the same for implantation in a body lumen
US8652204B2 (en) 2010-04-01 2014-02-18 Medtronic, Inc. Transcatheter valve with torsion spring fixation and related systems and methods
US8579964B2 (en) 2010-05-05 2013-11-12 Neovasc Inc. Transcatheter mitral valve prosthesis
CA2799459A1 (en) 2010-05-25 2011-12-01 Jenavalve Technology Inc. Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent
WO2011159779A2 (en) * 2010-06-15 2011-12-22 Mayo Foundation For Medical Education And Research Percutaneously deliverable valves
CN103153384B (en) 2010-06-28 2016-03-09 科利柏心脏瓣膜有限责任公司 For the device of device in the delivery of vascular of chamber
DK2590595T3 (en) 2010-07-09 2015-12-07 Highlife Sas Transcatheter atrioventricular heart valve prosthesis
WO2012082952A2 (en) 2010-12-14 2012-06-21 Colibri Heart Valve Llc Percutaneously deliverable heart valve including folded membrane cusps with integral leaflets
KR101312352B1 (en) * 2011-03-03 2013-09-27 부산대학교 산학협력단 Artificial cardiac valve and its manufacturing method and artificial valved conduit
US9554897B2 (en) 2011-04-28 2017-01-31 Neovasc Tiara Inc. Methods and apparatus for engaging a valve prosthesis with tissue
US9308087B2 (en) 2011-04-28 2016-04-12 Neovasc Tiara Inc. Sequentially deployed transcatheter mitral valve prosthesis
US8945209B2 (en) * 2011-05-20 2015-02-03 Edwards Lifesciences Corporation Encapsulated heart valve
US9289282B2 (en) 2011-05-31 2016-03-22 Edwards Lifesciences Corporation System and method for treating valve insufficiency or vessel dilatation
US20130023980A1 (en) * 2011-07-22 2013-01-24 William Joseph Drasler Oval Aortic Valve
US9668859B2 (en) 2011-08-05 2017-06-06 California Institute Of Technology Percutaneous heart valve delivery systems
CA3040390C (en) 2011-08-11 2022-03-15 Tendyne Holdings, Inc. Improvements for prosthetic valves and related inventions
US9554904B2 (en) * 2011-09-28 2017-01-31 Medtronic CV Luxembourg S.a.r.l. Distal tip assembly for a heart valve delivery catheter
US9827092B2 (en) 2011-12-16 2017-11-28 Tendyne Holdings, Inc. Tethers for prosthetic mitral valve
JP5978312B2 (en) 2011-12-20 2016-08-24 ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. Device for replacing a heart valve in a blood vessel
WO2013120082A1 (en) 2012-02-10 2013-08-15 Kassab Ghassan S Methods and uses of biological tissues for various stent and other medical applications
US9011515B2 (en) 2012-04-19 2015-04-21 Caisson Interventional, LLC Heart valve assembly systems and methods
CN102764169B (en) * 2012-04-19 2015-07-29 杭州启明医疗器械有限公司 Cardiac valve prosthesis and valve bracket thereof
US9427315B2 (en) 2012-04-19 2016-08-30 Caisson Interventional, LLC Valve replacement systems and methods
US9345573B2 (en) 2012-05-30 2016-05-24 Neovasc Tiara Inc. Methods and apparatus for loading a prosthesis onto a delivery system
WO2014022124A1 (en) 2012-07-28 2014-02-06 Tendyne Holdings, Inc. Improved multi-component designs for heart valve retrieval device, sealing structures and stent assembly
US9675454B2 (en) 2012-07-30 2017-06-13 Tendyne Holdings, Inc. Delivery systems and methods for transcatheter prosthetic valves
US20140074228A1 (en) * 2012-09-04 2014-03-13 Justin Negri Prosthetic heart valve
AU2014214700B2 (en) 2013-02-11 2018-01-18 Cook Medical Technologies Llc Expandable support frame and medical device
US10583002B2 (en) 2013-03-11 2020-03-10 Neovasc Tiara Inc. Prosthetic valve with anti-pivoting mechanism
US9681951B2 (en) 2013-03-14 2017-06-20 Edwards Lifesciences Cardiaq Llc Prosthesis with outer skirt and anchors
US9744037B2 (en) 2013-03-15 2017-08-29 California Institute Of Technology Handle mechanism and functionality for repositioning and retrieval of transcatheter heart valves
US9486306B2 (en) 2013-04-02 2016-11-08 Tendyne Holdings, Inc. Inflatable annular sealing device for prosthetic mitral valve
US11224510B2 (en) 2013-04-02 2022-01-18 Tendyne Holdings, Inc. Prosthetic heart valve and systems and methods for delivering the same
US10463489B2 (en) 2013-04-02 2019-11-05 Tendyne Holdings, Inc. Prosthetic heart valve and systems and methods for delivering the same
US9572665B2 (en) 2013-04-04 2017-02-21 Neovasc Tiara Inc. Methods and apparatus for delivering a prosthetic valve to a beating heart
US10478293B2 (en) 2013-04-04 2019-11-19 Tendyne Holdings, Inc. Retrieval and repositioning system for prosthetic heart valve
US9610159B2 (en) 2013-05-30 2017-04-04 Tendyne Holdings, Inc. Structural members for prosthetic mitral valves
CA2914856C (en) 2013-06-25 2021-03-09 Chad Perrin Thrombus management and structural compliance features for prosthetic heart valves
CN105555231B (en) 2013-08-01 2018-02-09 坦迪尼控股股份有限公司 External membrane of heart anchor and method
US9867694B2 (en) 2013-08-30 2018-01-16 Jenavalve Technology Inc. Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame
WO2015058039A1 (en) 2013-10-17 2015-04-23 Robert Vidlund Apparatus and methods for alignment and deployment of intracardiac devices
US9421094B2 (en) 2013-10-23 2016-08-23 Caisson Interventional, LLC Methods and systems for heart valve therapy
CA2924389C (en) 2013-10-28 2021-11-09 Tendyne Holdings, Inc. Prosthetic heart valve and systems and methods for delivering the same
US9526611B2 (en) 2013-10-29 2016-12-27 Tendyne Holdings, Inc. Apparatus and methods for delivery of transcatheter prosthetic valves
WO2015120122A2 (en) 2014-02-05 2015-08-13 Robert Vidlund Apparatus and methods for transfemoral delivery of prosthetic mitral valve
US9986993B2 (en) 2014-02-11 2018-06-05 Tendyne Holdings, Inc. Adjustable tether and epicardial pad system for prosthetic heart valve
CA2937566C (en) 2014-03-10 2023-09-05 Tendyne Holdings, Inc. Devices and methods for positioning and monitoring tether load for prosthetic mitral valve
EP2921139B1 (en) * 2014-03-18 2018-11-21 Nvt Ag Heartvalve implant
EA034896B1 (en) * 2014-05-09 2020-04-03 Фолдэкс, Инк. Replacement heart valve
US9974647B2 (en) 2014-06-12 2018-05-22 Caisson Interventional, LLC Two stage anchor and mitral valve assembly
US20160095701A1 (en) * 2014-10-07 2016-04-07 St. Jude Medical, Cardiology Division, Inc. Bi-Leaflet Mitral Valve Design
US9750607B2 (en) 2014-10-23 2017-09-05 Caisson Interventional, LLC Systems and methods for heart valve therapy
US9750605B2 (en) 2014-10-23 2017-09-05 Caisson Interventional, LLC Systems and methods for heart valve therapy
JP6826035B2 (en) 2015-01-07 2021-02-03 テンダイン ホールディングス,インコーポレイテッド Artificial mitral valve, and devices and methods for its delivery
JP6718459B2 (en) 2015-02-05 2020-07-08 テンダイン ホールディングス,インコーポレイテッド Expandable epicardial pad and device and methods of delivery thereof
WO2016168609A1 (en) 2015-04-16 2016-10-20 Tendyne Holdings, Inc. Apparatus and methods for delivery, repositioning, and retrieval of transcatheter prosthetic valves
EP3288495B1 (en) 2015-05-01 2019-09-25 JenaValve Technology, Inc. Device with reduced pacemaker rate in heart valve replacement
US10327894B2 (en) 2015-09-18 2019-06-25 Tendyne Holdings, Inc. Methods for delivery of prosthetic mitral valves
AU2016362474B2 (en) 2015-12-03 2021-04-22 Tendyne Holdings, Inc. Frame features for prosthetic mitral valves
JP6795591B2 (en) 2015-12-28 2020-12-02 テンダイン ホールディングス,インコーポレイテッド Atrial pocket closure for artificial heart valve
AU2016380345B2 (en) 2015-12-30 2021-10-28 Caisson Interventional, LLC Systems and methods for heart valve therapy
CN108882981B (en) 2016-01-29 2021-08-10 内奥瓦斯克迪亚拉公司 Prosthetic valve for preventing outflow obstruction
DE102016103843A1 (en) * 2016-03-03 2017-09-07 Biotronik Ag Reduction of paravalvular leakage through controlled thrombus buildup
US10470877B2 (en) 2016-05-03 2019-11-12 Tendyne Holdings, Inc. Apparatus and methods for anterior valve leaflet management
EP4183371A1 (en) 2016-05-13 2023-05-24 JenaValve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system
WO2017218375A1 (en) 2016-06-13 2017-12-21 Tendyne Holdings, Inc. Sequential delivery of two-part prosthetic mitral valve
EP3478224B1 (en) 2016-06-30 2022-11-02 Tendyne Holdings, Inc. Prosthetic heart valves and apparatus for delivery of same
EP3484411A1 (en) 2016-07-12 2019-05-22 Tendyne Holdings, Inc. Apparatus and methods for trans-septal retrieval of prosthetic heart valves
WO2018090148A1 (en) 2016-11-21 2018-05-24 Neovasc Tiara Inc. Methods and systems for rapid retraction of a transcatheter heart valve delivery system
WO2018138658A1 (en) 2017-01-27 2018-08-02 Jenavalve Technology, Inc. Heart valve mimicry
WO2018226915A1 (en) 2017-06-08 2018-12-13 Boston Scientific Scimed, Inc. Heart valve implant commissure support structure
CA3068164A1 (en) * 2017-06-30 2019-01-03 Ohio State Innovation Foundation Tri-leaflet prosthetic heart valve
CA3068176A1 (en) * 2017-06-30 2019-01-03 Ohio State Innovation Foundation Prosthetic heart valve with tri-leaflet design for use in percutaneous valve replacement procedures
WO2019014473A1 (en) 2017-07-13 2019-01-17 Tendyne Holdings, Inc. Prosthetic heart valves and apparatus and methods for delivery of same
WO2019036810A1 (en) 2017-08-25 2019-02-28 Neovasc Tiara Inc. Sequentially deployed transcatheter mitral valve prosthesis
WO2019046099A1 (en) 2017-08-28 2019-03-07 Tendyne Holdings, Inc. Prosthetic heart valves with tether coupling features
WO2019051476A1 (en) 2017-09-11 2019-03-14 Incubar, LLC Conduit vascular implant sealing device for reducing endoleak
CA3083533A1 (en) 2017-12-11 2019-06-20 California Institute Of Technology Systems, devices, and methods relating to the manufacture of intravascularly implantable prosthetic valves
US11737872B2 (en) 2018-11-08 2023-08-29 Neovasc Tiara Inc. Ventricular deployment of a transcatheter mitral valve prosthesis
CA3135753C (en) 2019-04-01 2023-10-24 Neovasc Tiara Inc. Controllably deployable prosthetic valve
CA3136334A1 (en) 2019-04-10 2020-10-15 Neovasc Tiara Inc. Prosthetic valve with natural blood flow
WO2020236931A1 (en) 2019-05-20 2020-11-26 Neovasc Tiara Inc. Introducer with hemostasis mechanism
CN114144144A (en) 2019-06-20 2022-03-04 内奥瓦斯克迪亚拉公司 Low-profile prosthetic mitral valve
US11648110B2 (en) 2019-12-05 2023-05-16 Tendyne Holdings, Inc. Braided anchor for mitral valve
US11648114B2 (en) 2019-12-20 2023-05-16 Tendyne Holdings, Inc. Distally loaded sheath and loading funnel
US11678980B2 (en) 2020-08-19 2023-06-20 Tendyne Holdings, Inc. Fully-transseptal apical pad with pulley for tensioning

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851000A (en) * 1987-07-31 1989-07-25 Pacific Biomedical Holdings, Ltd. Bioprosthetic valve stent
US8932349B2 (en) * 2004-09-02 2015-01-13 Boston Scientific Scimed, Inc. Cardiac valve, system, and method

Family Cites Families (558)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3451067A (en) 1966-06-16 1969-06-24 Daniel Lazo Jordan Heart valve
US3671979A (en) 1969-09-23 1972-06-27 Univ Utah Catheter mounted artificial heart valve for implanting in close proximity to a defective natural heart valve
US4291420A (en) 1973-11-09 1981-09-29 Medac Gesellschaft Fur Klinische Spezialpraparate Mbh Artificial heart valve
GB2056023B (en) * 1979-08-06 1983-08-10 Ross D N Bodnar E Stent for a cardiac valve
US7018407B1 (en) 1981-10-29 2006-03-28 Medtronic Valve holder for tricuspid heart valve
DE8327414U1 (en) * 1983-09-23 1984-02-02 Reichart, Bruno, Prof. Dr. HEART VALVE PROSTHESIS
US5275622A (en) 1983-12-09 1994-01-04 Harrison Medical Technologies, Inc. Endovascular grafting apparatus, system and method and devices for use therewith
DE3426300A1 (en) * 1984-07-17 1986-01-30 Doguhan Dr.med. 6000 Frankfurt Baykut TWO-WAY VALVE AND ITS USE AS A HEART VALVE PROSTHESIS
US4935030A (en) 1985-06-17 1990-06-19 Medtronic, Inc. Mechanical heart valve prosthesis
WO1988000459A1 (en) 1986-07-17 1988-01-28 Quotidian No. 100 Pty. Limited Prosthetic venous valve
US4661107A (en) * 1986-07-21 1987-04-28 Fink Irving E Heart valve
US4872874A (en) 1987-05-29 1989-10-10 Taheri Syde A Method and apparatus for transarterial aortic graft insertion and implantation
JPS6483251A (en) 1987-09-24 1989-03-29 Terumo Corp Instrument for securing inner diameter of cavity of tubular organ
IT1218947B (en) * 1988-01-12 1990-04-24 Sorin Biomedica Spa CARDIAC VALVE PROSTHESIS
SE8800244D0 (en) 1988-01-27 1988-01-27 Medical Innovation Ab DEVICE FOR CUTTING OF LEFT FLAVORS
US4994077A (en) * 1989-04-21 1991-02-19 Dobben Richard L Artificial heart valve for implantation in a blood vessel
US5609626A (en) 1989-05-31 1997-03-11 Baxter International Inc. Stent devices and support/restrictor assemblies for use in conjunction with prosthetic vascular grafts
DK0474748T3 (en) * 1989-05-31 1995-05-01 Baxter Int Biological flap prosthesis
AU632592B2 (en) 1989-06-19 1993-01-07 Hugh H. Trout Iii Aortic graft and method for repairing aneurysm
US5290300A (en) 1989-07-31 1994-03-01 Baxter International Inc. Flexible suture guide and holder
FR2657261A1 (en) 1990-01-19 1991-07-26 Bovyn Gilles Device for temporary implantation of a blood filter in a vein of the human body
DK124690D0 (en) * 1990-05-18 1990-05-18 Henning Rud Andersen FAT PROTECTION FOR IMPLEMENTATION IN THE BODY FOR REPLACEMENT OF NATURAL FLEET AND CATS FOR USE IN IMPLEMENTING A SUCH FAT PROTECTION
US5411552A (en) 1990-05-18 1995-05-02 Andersen; Henning R. Valve prothesis for implantation in the body and a catheter for implanting such valve prothesis
US5578071A (en) 1990-06-11 1996-11-26 Parodi; Juan C. Aortic graft
AR246020A1 (en) 1990-10-03 1994-03-30 Hector Daniel Barone Juan Carl A ball device for implanting an intraluminous aortic prosthesis, for repairing aneurysms.
DE9016236U1 (en) * 1990-11-29 1991-04-25 Anschuetz & Co Gmbh, 2300 Kiel, De
US5272909A (en) 1991-04-25 1993-12-28 Baxter International Inc. Method and device for testing venous valves
IT1245750B (en) * 1991-05-24 1994-10-14 Sorin Biomedica Emodialisi S R CARDIAC VALVE PROSTHESIS, PARTICULARLY FOR REPLACING THE AORTIC VALVE
US5370685A (en) 1991-07-16 1994-12-06 Stanford Surgical Technologies, Inc. Endovascular aortic valve replacement
US5163953A (en) 1992-02-10 1992-11-17 Vince Dennis J Toroidal artificial heart valve stent
US5258023A (en) 1992-02-12 1993-11-02 Reger Medical Development, Inc. Prosthetic heart valve
US5234448A (en) 1992-02-28 1993-08-10 Shadyside Hospital Method and apparatus for connecting and closing severed blood vessels
US5332402A (en) 1992-05-12 1994-07-26 Teitelbaum George P Percutaneously-inserted cardiac valve
US5982645A (en) 1992-08-25 1999-11-09 Square D Company Power conversion and distribution system
US5972030A (en) 1993-02-22 1999-10-26 Heartport, Inc. Less-invasive devices and methods for treatment of cardiac valves
US6010531A (en) * 1993-02-22 2000-01-04 Heartport, Inc. Less-invasive devices and methods for cardiac valve surgery
US5480423A (en) * 1993-05-20 1996-01-02 Boston Scientific Corporation Prosthesis delivery
US5713950A (en) 1993-11-01 1998-02-03 Cox; James L. Method of replacing heart valves using flexible tubes
FR2718951B1 (en) 1994-04-26 1996-07-26 Perouse Implant Laboratoire Tubular stent.
US5554185A (en) 1994-07-18 1996-09-10 Block; Peter C. Inflatable prosthetic cardiovascular valve for percutaneous transluminal implantation of same
DE69523074T2 (en) * 1994-07-29 2002-06-06 Edwards Lifesciences Corp METHOD FOR TREATING IMPLANTABLE BIOLOGICAL TISSUES TO REDUCE CALCIFICATION
IT1267463B1 (en) * 1994-09-27 1997-02-05 Alessandro Verona PROSTHETIC DUCT PARTICULARLY FOR THE TREATMENT OF CARDIOVASCULAR PATHOLOGIES.
FR2728457B1 (en) 1994-12-21 1997-03-21 Franceschi Claude ARTIFICIAL VALVE FOR BLOOD VESSEL
BE1009278A3 (en) * 1995-04-12 1997-01-07 Corvita Europ Guardian self-expandable medical device introduced in cavite body, and medical device with a stake as.
EP0831753B1 (en) * 1995-06-01 2005-12-28 Meadox Medicals, Inc. Implantable intraluminal prosthesis
DE69635479T2 (en) 1995-06-07 2006-06-08 St. Jude Medical, Inc., St. Paul PROSTHETIC HEARTLAP WITH ENLARGED LUMEN
US5716370A (en) * 1996-02-23 1998-02-10 Williamson, Iv; Warren Means for replacing a heart valve in a minimally invasive manner
US6402780B2 (en) 1996-02-23 2002-06-11 Cardiovascular Technologies, L.L.C. Means and method of replacing a heart valve in a minimally invasive manner
US5928916A (en) 1996-04-25 1999-07-27 Medtronic, Inc. Ionic attachment of biomolecules with a guanidino moiety to medical device surfaces
BR9709867A (en) 1996-06-20 2000-01-11 Sulzer Vascutek Ltda Device for retaining a prosthesis in a passage of the body device for fixing a prosthesis on an internal surface of a body passage, prosthetic device, prosthesis and process for fixing a prosthetic device, for repairing a vessel and for inserting a prosthesis in a passage of the body.
US5855601A (en) * 1996-06-21 1999-01-05 The Trustees Of Columbia University In The City Of New York Artificial heart valve and method and device for implanting the same
US5741326A (en) * 1996-07-15 1998-04-21 Cordis Corporation Low profile thermally set wrapped cover for a percutaneously deployed stent
AU3733497A (en) 1996-07-19 1998-02-10 Regents Of The University Of Minnesota Recombinant sef14 fimbrial protein from salmonella
US6764509B2 (en) 1996-09-06 2004-07-20 Carbomedics Inc. Prosthetic heart valve with surface modification
US5895419A (en) * 1996-09-30 1999-04-20 St. Jude Medical, Inc. Coated prosthetic cardiac device
NL1004827C2 (en) 1996-12-18 1998-06-19 Surgical Innovations Vof Device for regulating blood circulation.
US5879320A (en) * 1996-12-23 1999-03-09 Cazenave; Craig Richard Implantable vascular device
EP0850607A1 (en) 1996-12-31 1998-07-01 Cordis Corporation Valve prosthesis for implantation in body channels
US5735859A (en) * 1997-02-14 1998-04-07 Cathco, Inc. Distally attachable and releasable sheath for a stent delivery system
US5928281A (en) 1997-03-27 1999-07-27 Baxter International Inc. Tissue heart valves
US5961549A (en) * 1997-04-03 1999-10-05 Baxter International Inc. Multi-leaflet bioprosthetic heart valve
AU744343B2 (en) 1997-04-11 2002-02-21 Transvascular, Inc. Methods and apparatus for transmyocardial direct coronary revascularization
WO1999000059A1 (en) 1997-06-27 1999-01-07 The Trustees Of Columbia University In The City Of New York Method and apparatus for circulatory valve repair
DE19731834A1 (en) 1997-07-24 1999-06-17 Ernst Peter Prof Dr M Strecker Implantation device
FR2768324B1 (en) 1997-09-12 1999-12-10 Jacques Seguin SURGICAL INSTRUMENT FOR PERCUTANEOUSLY FIXING TWO AREAS OF SOFT TISSUE, NORMALLY MUTUALLY REMOTE, TO ONE ANOTHER
US6361545B1 (en) 1997-09-26 2002-03-26 Cardeon Corporation Perfusion filter catheter
US5910170A (en) 1997-12-17 1999-06-08 St. Jude Medical, Inc. Prosthetic heart valve stent utilizing mounting clips
EP1049425B1 (en) 1997-12-29 2009-11-25 Cleveland Clinic Foundation The System for minimally invasive insertion of a bioprosthetic heart valve
US6530952B2 (en) 1997-12-29 2003-03-11 The Cleveland Clinic Foundation Bioprosthetic cardiovascular valve system
US6074418A (en) 1998-04-20 2000-06-13 St. Jude Medical, Inc. Driver tool for heart valve prosthesis fasteners
US6007557A (en) 1998-04-29 1999-12-28 Embol-X, Inc. Adjustable blood filtration system
JP4399585B2 (en) * 1998-06-02 2010-01-20 クック インコーポレイティド Multi-sided medical device
US7452371B2 (en) 1999-06-02 2008-11-18 Cook Incorporated Implantable vascular device
US6250308B1 (en) 1998-06-16 2001-06-26 Cardiac Concepts, Inc. Mitral valve annuloplasty ring and method of implanting
US6117169A (en) 1998-06-24 2000-09-12 Sulzer Carbomedics Inc. Living hinge attachment of leaflet to a valve body
US6165183A (en) 1998-07-15 2000-12-26 St. Jude Medical, Inc. Mitral and tricuspid valve repair
US6641610B2 (en) 1998-09-10 2003-11-04 Percardia, Inc. Valve designs for left ventricular conduits
US6254564B1 (en) 1998-09-10 2001-07-03 Percardia, Inc. Left ventricular conduit with blood vessel graft
US6921811B2 (en) 1998-09-22 2005-07-26 Biosurface Engineering Technologies, Inc. Bioactive coating composition and methods
US6355030B1 (en) * 1998-09-25 2002-03-12 Cardiothoracic Systems, Inc. Instruments and methods employing thermal energy for the repair and replacement of cardiac valves
US6051014A (en) * 1998-10-13 2000-04-18 Embol-X, Inc. Percutaneous filtration catheter for valve repair surgery and methods of use
US6540780B1 (en) 1998-11-23 2003-04-01 Medtronic, Inc. Porous synthetic vascular grafts with oriented ingrowth channels
WO2000032750A1 (en) 1998-11-24 2000-06-08 Regents Of The University Of Minnesota Transgenic circulating endothelial cells
US20040267349A1 (en) 2003-06-27 2004-12-30 Kobi Richter Amorphous metal alloy medical devices
FR2788217A1 (en) * 1999-01-12 2000-07-13 Brice Letac PROSTHETIC VALVE IMPLANTABLE BY CATHETERISM, OR SURGICAL
US6558418B2 (en) 1999-01-26 2003-05-06 Edwards Lifesciences Corporation Flexible heart valve
ATE379998T1 (en) * 1999-01-26 2007-12-15 Edwards Lifesciences Corp FLEXIBLE HEART VALVE
US6736845B2 (en) 1999-01-26 2004-05-18 Edwards Lifesciences Corporation Holder for flexible heart valve
WO2000042951A1 (en) * 1999-01-26 2000-07-27 Edwards Lifesciences Corporation Anatomical orifice sizers and methods of orifice sizing
US6896690B1 (en) 2000-01-27 2005-05-24 Viacor, Inc. Cardiac valve procedure methods and devices
US6364905B1 (en) 1999-01-27 2002-04-02 Sulzer Carbomedics Inc. Tri-composite, full root, stentless valve
DE19904975A1 (en) 1999-02-06 2000-09-14 Impella Cardiotech Ag Device for intravascular heart valve surgery
US6425916B1 (en) 1999-02-10 2002-07-30 Michi E. Garrison Methods and devices for implanting cardiac valves
US6666886B1 (en) 1999-02-16 2003-12-23 Regents Of The University Of Minnesota Tissue equivalent approach to a tissue-engineered cardiovascular valve
US6110201A (en) 1999-02-18 2000-08-29 Venpro Bifurcated biological pulmonary valved conduit
US6139575A (en) 1999-04-02 2000-10-31 Medtronic, Inc. Hybrid mechanical heart valve prosthesis
US6752813B2 (en) 1999-04-09 2004-06-22 Evalve, Inc. Methods and devices for capturing and fixing leaflets in valve repair
US20040044350A1 (en) * 1999-04-09 2004-03-04 Evalve, Inc. Steerable access sheath and methods of use
US7563267B2 (en) * 1999-04-09 2009-07-21 Evalve, Inc. Fixation device and methods for engaging tissue
AU770243B2 (en) * 1999-04-09 2004-02-19 Evalve, Inc. Methods and apparatus for cardiac valve repair
US6666885B2 (en) 1999-04-16 2003-12-23 Carbomedics Inc. Heart valve leaflet
EP1584307A3 (en) 1999-04-23 2005-10-19 St.Jude Medical ATG, Inc. Artificial heart valve with attachment fingers
JP2002541974A (en) * 1999-04-28 2002-12-10 セント・ジュード・メディカル・インコーポレーテッド Heart substitute valve
AU4673700A (en) 1999-05-06 2000-11-21 Venpro Corporation Implant for restoring venous valvular function
US6309417B1 (en) 1999-05-12 2001-10-30 Paul A. Spence Heart valve and apparatus for replacement thereof
US6790229B1 (en) 1999-05-25 2004-09-14 Eric Berreklouw Fixing device, in particular for fixing to vascular wall tissue
US6478819B2 (en) * 1999-05-27 2002-11-12 Sulzer Carbomedics Inc. Prosthetic heart valves with flexible post geometry
US7628803B2 (en) 2001-02-05 2009-12-08 Cook Incorporated Implantable vascular device
US6241763B1 (en) 1999-06-08 2001-06-05 William J. Drasler In situ venous valve device and method of formation
SE514718C2 (en) * 1999-06-29 2001-04-09 Jan Otto Solem Apparatus for treating defective closure of the mitral valve apparatus
US6997951B2 (en) 1999-06-30 2006-02-14 Edwards Lifesciences Ag Method and device for treatment of mitral insufficiency
US7192442B2 (en) 1999-06-30 2007-03-20 Edwards Lifesciences Ag Method and device for treatment of mitral insufficiency
US6235044B1 (en) 1999-08-04 2001-05-22 Scimed Life Systems, Inc. Percutaneous catheter and guidewire for filtering during ablation of mycardial or vascular tissue
US20030055492A1 (en) 1999-08-20 2003-03-20 Shaolian Samuel M. Transluminally implantable venous valve
DE10084973T1 (en) 1999-08-27 2002-07-25 Kimberly Clark Co Absorbent object with a folded, expandable, absorbent layer
US6315793B1 (en) 1999-09-08 2001-11-13 Medical Carbon Research Institute, Llc Prosthetic venous valves
JP3443077B2 (en) 1999-09-20 2003-09-02 ソニー株式会社 Robot motion pattern generation device and motion pattern generation method, and robot
DE19945587A1 (en) 1999-09-23 2001-05-10 Co Don Ag Procedure for inserting implants into human organs
US6312447B1 (en) 1999-10-13 2001-11-06 The General Hospital Corporation Devices and methods for percutaneous mitral valve repair
US6626930B1 (en) 1999-10-21 2003-09-30 Edwards Lifesciences Corporation Minimally invasive mitral valve repair method and apparatus
US6440164B1 (en) * 1999-10-21 2002-08-27 Scimed Life Systems, Inc. Implantable prosthetic valve
JP2001120582A (en) 1999-10-22 2001-05-08 Gunze Ltd Artificial cardiac valve and method of manufacturing the same
US6926730B1 (en) 2000-10-10 2005-08-09 Medtronic, Inc. Minimally invasive valve repair procedure and apparatus
AU1068800A (en) 1999-11-10 2001-06-06 Impsa International Incorporated Prosthetic heart valve
US8579966B2 (en) 1999-11-17 2013-11-12 Medtronic Corevalve Llc Prosthetic valve for transluminal delivery
FR2800984B1 (en) 1999-11-17 2001-12-14 Jacques Seguin DEVICE FOR REPLACING A HEART VALVE PERCUTANEOUSLY
US7018406B2 (en) 1999-11-17 2006-03-28 Corevalve Sa Prosthetic valve for transluminal delivery
US6458153B1 (en) 1999-12-31 2002-10-01 Abps Venture One, Ltd. Endoluminal cardiac and venous valve prostheses and methods of manufacture and delivery thereof
US6709457B1 (en) * 1999-11-24 2004-03-23 St. Jude Medical, Inc. Attachment of suture cuff to prosthetic heart valve
SE514886C2 (en) 1999-12-14 2001-05-14 Jcl Technic Ab Vascular valve, such as heart valve, and process for its manufacture
US7052507B2 (en) 1999-12-24 2006-05-30 Toray Industries, Inc. Catheter with balloon
US6942694B2 (en) 2000-01-14 2005-09-13 Viacor, Inc. Tissue annuloplasty band and apparatus and method for fashioning, sizing and implanting the same
WO2001054745A2 (en) 2000-01-25 2001-08-02 Edwards Lifesciences Corporation Bioactive coatings to prevent tissue overgrowth on artificial heart valves
JP2005503178A (en) 2000-01-25 2005-02-03 ボストン サイエンティフィック リミテッド Manufacturing medical devices by vapor deposition
US6769434B2 (en) 2000-06-30 2004-08-03 Viacor, Inc. Method and apparatus for performing a procedure on a cardiac valve
US7749245B2 (en) * 2000-01-27 2010-07-06 Medtronic, Inc. Cardiac valve procedure methods and devices
ES2307590T3 (en) 2000-01-27 2008-12-01 3F Therapeutics, Inc HEART VALVE PROTESICA.
US6872226B2 (en) 2001-01-29 2005-03-29 3F Therapeutics, Inc. Method of cutting material for use in implantable medical device
US6402781B1 (en) * 2000-01-31 2002-06-11 Mitralife Percutaneous mitral annuloplasty and cardiac reinforcement
US7296577B2 (en) 2000-01-31 2007-11-20 Edwards Lifescience Ag Transluminal mitral annuloplasty with active anchoring
US6989028B2 (en) 2000-01-31 2006-01-24 Edwards Lifesciences Ag Medical system and method for remodeling an extravascular tissue structure
WO2001056512A1 (en) * 2000-02-02 2001-08-09 Snyders Robert V Artificial heart valve
US6821297B2 (en) 2000-02-02 2004-11-23 Robert V. Snyders Artificial heart valve, implantation instrument and method therefor
US6797002B2 (en) 2000-02-02 2004-09-28 Paul A. Spence Heart valve repair apparatus and methods
US20050070999A1 (en) 2000-02-02 2005-03-31 Spence Paul A. Heart valve repair apparatus and methods
AU2001245432B2 (en) * 2000-03-03 2006-04-27 Cook Medical Technologies Llc Bulbous valve and stent for treating vascular reflux
US20030229393A1 (en) 2001-03-15 2003-12-11 Kutryk Michael J. B. Medical device with coating that promotes cell adherence and differentiation
US6454799B1 (en) 2000-04-06 2002-09-24 Edwards Lifesciences Corporation Minimally-invasive heart valves and methods of use
US6652583B2 (en) 2000-04-07 2003-11-25 Rhode Island Hospital Cardiac valve replacement
WO2001080782A1 (en) * 2000-04-27 2001-11-01 Axel Haverich Individual venous valve prosthesis
US7083628B2 (en) * 2002-09-03 2006-08-01 Edwards Lifesciences Corporation Single catheter mitral valve repair device and method for use
US6610088B1 (en) 2000-05-03 2003-08-26 Shlomo Gabbay Biologically covered heart valve prosthesis
US6419695B1 (en) 2000-05-22 2002-07-16 Shlomo Gabbay Cardiac prosthesis for helping improve operation of a heart valve
US6869444B2 (en) 2000-05-22 2005-03-22 Shlomo Gabbay Low invasive implantable cardiac prosthesis and method for helping improve operation of a heart valve
US8366769B2 (en) 2000-06-01 2013-02-05 Edwards Lifesciences Corporation Low-profile, pivotable heart valve sewing ring
US6805711B2 (en) 2000-06-02 2004-10-19 3F Therapeutics, Inc. Expandable medical implant and percutaneous delivery
US20050043757A1 (en) 2000-06-12 2005-02-24 Michael Arad Medical devices formed from shape memory alloys displaying a stress-retained martensitic state and method for use thereof
AU2001268535A1 (en) 2000-06-20 2002-01-02 Starion Instruments, Inc. Devices and methods for repair of valves in the human body
US6840246B2 (en) * 2000-06-20 2005-01-11 University Of Maryland, Baltimore Apparatuses and methods for performing minimally invasive diagnostic and surgical procedures inside of a beating heart
US6702826B2 (en) 2000-06-23 2004-03-09 Viacor, Inc. Automated annular plication for mitral valve repair
US6676698B2 (en) 2000-06-26 2004-01-13 Rex Medicol, L.P. Vascular device with valve for approximating vessel wall
US6695878B2 (en) 2000-06-26 2004-02-24 Rex Medical, L.P. Vascular device for valve leaflet apposition
SE0002514D0 (en) 2000-06-30 2000-06-30 Pacesetter Ab Medical device
US7077861B2 (en) 2000-07-06 2006-07-18 Medtentia Ab Annuloplasty instrument
US6419696B1 (en) 2000-07-06 2002-07-16 Paul A. Spence Annuloplasty devices and related heart valve repair methods
US6695817B1 (en) * 2000-07-11 2004-02-24 Icu Medical, Inc. Medical valve with positive flow characteristics
SE0002878D0 (en) * 2000-08-11 2000-08-11 Kimblad Ola Device and method of treatment of atrioventricular regurgitation
US6635085B1 (en) 2000-08-17 2003-10-21 Carbomedics Inc. Heart valve stent with alignment posts
US6572652B2 (en) 2000-08-29 2003-06-03 Venpro Corporation Method and devices for decreasing elevated pulmonary venous pressure
US6846325B2 (en) * 2000-09-07 2005-01-25 Viacor, Inc. Fixation band for affixing a prosthetic heart valve to tissue
WO2002022054A1 (en) 2000-09-12 2002-03-21 Gabbay S Valvular prosthesis and method of using same
US20060142848A1 (en) 2000-09-12 2006-06-29 Shlomo Gabbay Extra-anatomic aortic valve placement
DE10046550A1 (en) 2000-09-19 2002-03-28 Adiam Life Science Ag Prosthetic mitral heart valve consists of support housing with base ring and two stanchions
US8956407B2 (en) 2000-09-20 2015-02-17 Mvrx, Inc. Methods for reshaping a heart valve annulus using a tensioning implant
US8784482B2 (en) 2000-09-20 2014-07-22 Mvrx, Inc. Method of reshaping a heart valve annulus using an intravascular device
WO2004030568A2 (en) 2002-10-01 2004-04-15 Ample Medical, Inc. Device and method for repairing a native heart valve leaflet
US20050228422A1 (en) 2002-11-26 2005-10-13 Ample Medical, Inc. Devices, systems, and methods for reshaping a heart valve annulus, including the use of magnetic tools
WO2004030570A2 (en) 2002-10-01 2004-04-15 Ample Medical, Inc. Devices for retaining native heart valve leaflet
US6893459B1 (en) 2000-09-20 2005-05-17 Ample Medical, Inc. Heart valve annulus device and method of using same
US20060106279A1 (en) 2004-05-14 2006-05-18 Ample Medical, Inc. Devices, systems, and methods for reshaping a heart valve annulus, including the use of a bridge implant having an adjustable bridge stop
US20060106278A1 (en) 2004-05-14 2006-05-18 Ample Medical, Inc. Devices, systems, and methods for reshaping a heart valve annulus, including the use of an adjustable bridge implant system
US6461382B1 (en) 2000-09-22 2002-10-08 Edwards Lifesciences Corporation Flexible heart valve having moveable commissures
US6932838B2 (en) 2000-09-29 2005-08-23 Tricardia, Llc Venous valvuloplasty device and method
US6602288B1 (en) 2000-10-05 2003-08-05 Edwards Lifesciences Corporation Minimally-invasive annuloplasty repair segment delivery template, system and method of use
US6723038B1 (en) 2000-10-06 2004-04-20 Myocor, Inc. Methods and devices for improving mitral valve function
DE10049865B8 (en) 2000-10-09 2008-10-30 Universitätsklinikum Freiburg Device for removing an aortic valve on the human heart by means of a minimally invasive surgical procedure
DE10050092A1 (en) * 2000-10-09 2002-04-11 Adiam Life Science Ag Prosthetic mitral valve comprises base and valve flaps which have core which is more rigid than their surface layer
US6918917B1 (en) 2000-10-10 2005-07-19 Medtronic, Inc. Minimally invasive annuloplasty procedure and apparatus
US6913608B2 (en) 2000-10-23 2005-07-05 Viacor, Inc. Automated annular plication for mitral valve repair
US6602286B1 (en) * 2000-10-26 2003-08-05 Ernst Peter Strecker Implantable valve system
US6974476B2 (en) 2003-05-05 2005-12-13 Rex Medical, L.P. Percutaneous aortic valve
US6730122B1 (en) 2000-11-28 2004-05-04 St. Jude Medical, Inc. Prosthetic heart valve with increased lumen
AU2002236640A1 (en) 2000-12-15 2002-06-24 Viacor, Inc. Apparatus and method for replacing aortic valve
US6716244B2 (en) * 2000-12-20 2004-04-06 Carbomedics, Inc. Sewing cuff assembly for heart valves
US6964682B2 (en) 2000-12-21 2005-11-15 Edwards Lifesciences Corporation Heart valve holder that resist suture looping
US6966925B2 (en) 2000-12-21 2005-11-22 Edwards Lifesciences Corporation Heart valve holder and method for resisting suture looping
US6669725B2 (en) 2000-12-28 2003-12-30 Centerpulse Biologics Inc. Annuloplasty ring for regeneration of diseased or damaged heart valve annulus
US6810882B2 (en) 2001-01-30 2004-11-02 Ev3 Santa Rosa, Inc. Transluminal mitral annuloplasty
US7510576B2 (en) 2001-01-30 2009-03-31 Edwards Lifesciences Ag Transluminal mitral annuloplasty
CA2437824C (en) 2001-02-05 2008-09-23 Viacor, Inc. Apparatus and method for reducing mitral regurgitation
US20050182483A1 (en) 2004-02-11 2005-08-18 Cook Incorporated Percutaneously placed prosthesis with thromboresistant valve portion
AU2002240288B2 (en) 2001-02-05 2006-05-18 Viacor, Inc. Method and apparatus for improving mitral valve function
US20020107531A1 (en) 2001-02-06 2002-08-08 Schreck Stefan G. Method and system for tissue repair using dual catheters
US6955689B2 (en) 2001-03-15 2005-10-18 Medtronic, Inc. Annuloplasty band and method
US6786924B2 (en) 2001-03-15 2004-09-07 Medtronic, Inc. Annuloplasty band and method
US6916338B2 (en) 2001-03-16 2005-07-12 Mayo Foundation For Medical Education And Research Synthetic leaflets for heart valve repair or replacement
US6503272B2 (en) * 2001-03-21 2003-01-07 Cordis Corporation Stent-based venous valves
CA2441886C (en) 2001-03-23 2009-07-21 Viacor, Incorporated Method and apparatus for reducing mitral regurgitation
US7556646B2 (en) * 2001-09-13 2009-07-07 Edwards Lifesciences Corporation Methods and apparatuses for deploying minimally-invasive heart valves
AUPR389201A0 (en) 2001-03-23 2001-04-12 Lane, Rodney James Improvements in design of external vendus valve stents for the correction fo incompetent vendods valves
US7186264B2 (en) 2001-03-29 2007-03-06 Viacor, Inc. Method and apparatus for improving mitral valve function
US6958076B2 (en) 2001-04-16 2005-10-25 Biomedical Research Associates Inc. Implantable venous valve
US7037334B1 (en) 2001-04-24 2006-05-02 Mitralign, Inc. Method and apparatus for catheter-based annuloplasty using local plications
US6619291B2 (en) * 2001-04-24 2003-09-16 Edwin J. Hlavka Method and apparatus for catheter-based annuloplasty
US20050125011A1 (en) 2001-04-24 2005-06-09 Spence Paul A. Tissue fastening systems and methods utilizing magnetic guidance
DE10121210B4 (en) 2001-04-30 2005-11-17 Universitätsklinikum Freiburg Anchoring element for the intraluminal anchoring of a heart valve replacement and method for its production
AU2002254758A1 (en) 2001-04-30 2002-11-11 Francisco J. Osse Replacement venous valve
US6682558B2 (en) 2001-05-10 2004-01-27 3F Therapeutics, Inc. Delivery system for a stentless valve bioprosthesis
US6676702B2 (en) * 2001-05-14 2004-01-13 Cardiac Dimensions, Inc. Mitral valve therapy assembly and method
US6800090B2 (en) * 2001-05-14 2004-10-05 Cardiac Dimensions, Inc. Mitral valve therapy device, system and method
US6858039B2 (en) * 2002-07-08 2005-02-22 Edwards Lifesciences Corporation Mitral valve annuloplasty ring having a posterior bow
US6936067B2 (en) 2001-05-17 2005-08-30 St. Jude Medical Inc. Prosthetic heart valve with slit stent
ITMI20011012A1 (en) 2001-05-17 2002-11-17 Ottavio Alfieri ANNULAR PROSTHESIS FOR MITRAL VALVE
US20020173811A1 (en) 2001-05-21 2002-11-21 Hosheng Tu Apparatus and methods for valve removal
US7544206B2 (en) 2001-06-29 2009-06-09 Medtronic, Inc. Method and apparatus for resecting and replacing an aortic valve
FR2826863B1 (en) * 2001-07-04 2003-09-26 Jacques Seguin ASSEMBLY FOR PLACING A PROSTHETIC VALVE IN A BODY CONDUIT
US7547322B2 (en) 2001-07-19 2009-06-16 The Cleveland Clinic Foundation Prosthetic valve and method for making same
FR2828091B1 (en) * 2001-07-31 2003-11-21 Seguin Jacques ASSEMBLY ALLOWING THE PLACEMENT OF A PROTHETIC VALVE IN A BODY DUCT
US6726716B2 (en) 2001-08-24 2004-04-27 Edwards Lifesciences Corporation Self-molding annuloplasty ring
US6749630B2 (en) 2001-08-28 2004-06-15 Edwards Lifesciences Corporation Tricuspid ring and template
US6723122B2 (en) 2001-08-30 2004-04-20 Edwards Lifesciences Corporation Container and method for storing and delivering minimally-invasive heart valves
JP4458845B2 (en) 2001-10-01 2010-04-28 アンプル メディカル,インコーポレイテッド Medical device
US6893460B2 (en) 2001-10-11 2005-05-17 Percutaneous Valve Technologies Inc. Implantable prosthetic valve
US7144363B2 (en) 2001-10-16 2006-12-05 Extensia Medical, Inc. Systems for heart treatment
US20060020336A1 (en) 2001-10-23 2006-01-26 Liddicoat John R Automated annular plication for mitral valve repair
US6726715B2 (en) 2001-10-23 2004-04-27 Childrens Medical Center Corporation Fiber-reinforced heart valve prosthesis
US7052487B2 (en) 2001-10-26 2006-05-30 Cohn William E Method and apparatus for reducing mitral regurgitation
US20040044403A1 (en) * 2001-10-30 2004-03-04 Joyce Bischoff Tissue-engineered vascular structures
US7311729B2 (en) 2002-01-30 2007-12-25 Cardiac Dimensions, Inc. Device and method for modifying the shape of a body organ
US6824562B2 (en) 2002-05-08 2004-11-30 Cardiac Dimensions, Inc. Body lumen device anchor, device and assembly
US6949122B2 (en) 2001-11-01 2005-09-27 Cardiac Dimensions, Inc. Focused compression mitral valve device and method
US6805710B2 (en) 2001-11-13 2004-10-19 Edwards Lifesciences Corporation Mitral valve annuloplasty ring for molding left ventricle geometry
US6575971B2 (en) 2001-11-15 2003-06-10 Quantum Cor, Inc. Cardiac valve leaflet stapler device and methods thereof
US6719784B2 (en) * 2001-11-21 2004-04-13 Scimed Life Systems, Inc. Counter rotational layering of ePTFE to improve mechanical properties of a prosthesis
US20050228479A1 (en) 2001-11-29 2005-10-13 Cook Incorporated Medical device delivery system
US6976995B2 (en) 2002-01-30 2005-12-20 Cardiac Dimensions, Inc. Fixed length anchor and pull mitral valve device and method
US6908478B2 (en) 2001-12-05 2005-06-21 Cardiac Dimensions, Inc. Anchor and pull mitral valve device and method
US6793673B2 (en) 2002-12-26 2004-09-21 Cardiac Dimensions, Inc. System and method to effect mitral valve annulus of a heart
US7179282B2 (en) * 2001-12-05 2007-02-20 Cardiac Dimensions, Inc. Device and method for modifying the shape of a body organ
US6978176B2 (en) 2001-12-08 2005-12-20 Lattouf Omar M Treatment for patient with congestive heart failure
US6755857B2 (en) 2001-12-12 2004-06-29 Sulzer Carbomedics Inc. Polymer heart valve with perforated stent and sewing cuff
JP4230915B2 (en) 2001-12-21 2009-02-25 シムチャ ミロ Annuloplasty ring transplantation system
US6951573B1 (en) 2001-12-22 2005-10-04 Dilling Emery W Prosthetic aortic valve
US20030120340A1 (en) 2001-12-26 2003-06-26 Jan Liska Mitral and tricuspid valve repair
US7201771B2 (en) 2001-12-27 2007-04-10 Arbor Surgical Technologies, Inc. Bioprosthetic heart valve
US6881224B2 (en) 2001-12-28 2005-04-19 St. Jude Medical, Inc. Fatigue test for prosthetic stent
AU2002360066B2 (en) 2001-12-28 2008-11-06 Edwards Lifesciences Ag Delayed memory device
US7033390B2 (en) * 2002-01-02 2006-04-25 Medtronic, Inc. Prosthetic heart valve system
US8308797B2 (en) 2002-01-04 2012-11-13 Colibri Heart Valve, LLC Percutaneously implantable replacement heart valve device and method of making same
US20030130729A1 (en) 2002-01-04 2003-07-10 David Paniagua Percutaneously implantable replacement heart valve device and method of making same
US6764510B2 (en) 2002-01-09 2004-07-20 Myocor, Inc. Devices and methods for heart valve treatment
US7125420B2 (en) 2002-02-05 2006-10-24 Viacor, Inc. Method and apparatus for improving mitral valve function
WO2003070124A2 (en) 2002-02-20 2003-08-28 Osse Francisco J Venous bi-valve
DE10208202A1 (en) 2002-02-26 2003-09-11 Karlsruhe Forschzent vein graft
US6974464B2 (en) 2002-02-28 2005-12-13 3F Therapeutics, Inc. Supportless atrioventricular heart valve and minimally invasive delivery systems thereof
US7048754B2 (en) 2002-03-01 2006-05-23 Evalve, Inc. Suture fasteners and methods of use
US6716241B2 (en) * 2002-03-05 2004-04-06 John G. Wilder Venous valve and graft combination
US7004958B2 (en) 2002-03-06 2006-02-28 Cardiac Dimensions, Inc. Transvenous staples, assembly and method for mitral valve repair
US6797001B2 (en) 2002-03-11 2004-09-28 Cardiac Dimensions, Inc. Device, assembly and method for mitral valve repair
US6719786B2 (en) 2002-03-18 2004-04-13 Medtronic, Inc. Flexible annuloplasty prosthesis and holder
US7163556B2 (en) * 2002-03-21 2007-01-16 Providence Health System - Oregon Bioprosthesis and method for suturelessly making same
US7094244B2 (en) 2002-03-26 2006-08-22 Edwards Lifesciences Corporation Sequential heart valve leaflet repair device and method of use
US6752828B2 (en) 2002-04-03 2004-06-22 Scimed Life Systems, Inc. Artificial valve
US7160320B2 (en) 2002-04-16 2007-01-09 The International Heart Institute Of Montana Foundation Reed valve for implantation into mammalian blood vessels and heart with optional temporary or permanent support
US7125418B2 (en) 2002-04-16 2006-10-24 The International Heart Institute Of Montana Foundation Sigmoid valve and method for its percutaneous implantation
AU2003228528A1 (en) * 2002-04-16 2003-11-03 Viacor, Inc. Method and apparatus for resecting and replacing an aortic valve
DE10217559B4 (en) 2002-04-19 2004-02-19 Universitätsklinikum Freiburg Device for minimally invasive, intravascular aortic valve extraction
FR2838631B1 (en) 2002-04-23 2004-12-24 Engeneering And Technological METHOD FOR PRODUCING AN AORTIC OR MITRAL HEART VALVE PROSTHESIS AND AORTIC OR MITRAL HEART VALVE PROSTHESIS THUS OBTAINED
US6761735B2 (en) 2002-04-25 2004-07-13 Medtronic, Inc. Heart valve fixation process and apparatus
US7331993B2 (en) 2002-05-03 2008-02-19 The General Hospital Corporation Involuted endovascular valve and method of construction
EP2039325A1 (en) 2002-05-08 2009-03-25 Cardiac Dimensions, Inc. Device for modifying the shape of a body organ
US7351256B2 (en) 2002-05-10 2008-04-01 Cordis Corporation Frame based unidirectional flow prosthetic implant
US7270675B2 (en) * 2002-05-10 2007-09-18 Cordis Corporation Method of forming a tubular membrane on a structural frame
EP1507492A1 (en) * 2002-05-10 2005-02-23 Cordis Corporation Method of making a medical device having a thin wall tubular membrane over a structural frame
US20030229394A1 (en) 2002-06-06 2003-12-11 Ogle Matthew F. Processed tissue for medical device formation
AU2003247526A1 (en) * 2002-06-12 2003-12-31 Mitral Interventions, Inc. Method and apparatus for tissue connection
US8287555B2 (en) 2003-02-06 2012-10-16 Guided Delivery Systems, Inc. Devices and methods for heart valve repair
US7753924B2 (en) 2003-09-04 2010-07-13 Guided Delivery Systems, Inc. Delivery devices and methods for heart valve repair
US20050216078A1 (en) 2002-06-13 2005-09-29 Guided Delivery Systems, Inc. Delivery devices and methods for heart valve repair
AU2003245507A1 (en) 2002-06-13 2003-12-31 Guided Delivery Systems, Inc. Devices and methods for heart valve repair
US7753858B2 (en) 2002-06-13 2010-07-13 Guided Delivery Systems, Inc. Delivery devices and methods for heart valve repair
US7666193B2 (en) 2002-06-13 2010-02-23 Guided Delivery Sytems, Inc. Delivery devices and methods for heart valve repair
US7758637B2 (en) 2003-02-06 2010-07-20 Guided Delivery Systems, Inc. Delivery devices and methods for heart valve repair
US7753922B2 (en) 2003-09-04 2010-07-13 Guided Delivery Systems, Inc. Devices and methods for cardiac annulus stabilization and treatment
US20040243227A1 (en) 2002-06-13 2004-12-02 Guided Delivery Systems, Inc. Delivery devices and methods for heart valve repair
US7959674B2 (en) 2002-07-16 2011-06-14 Medtronic, Inc. Suture locking assembly and method of use
US7578843B2 (en) * 2002-07-16 2009-08-25 Medtronic, Inc. Heart valve prosthesis
US7172625B2 (en) * 2002-07-16 2007-02-06 Medtronic, Inc. Suturing rings for implantable heart valve prostheses
US6761734B2 (en) 2002-07-22 2004-07-13 William S. Suhr Segmented balloon catheter for stenting bifurcation lesions
US20040024452A1 (en) * 2002-08-02 2004-02-05 Kruse Steven D. Valved prostheses with preformed tissue leaflets
US8172856B2 (en) * 2002-08-02 2012-05-08 Cedars-Sinai Medical Center Methods and apparatus for atrioventricular valve repair
DE20321838U1 (en) 2002-08-13 2011-02-10 JenaValve Technology Inc., Wilmington Device for anchoring and aligning heart valve prostheses
EP1534146B1 (en) 2002-08-13 2008-01-23 The General Hospital Corporation Cardiac devices for percutaneous repair of atrioventricular valves
US7041132B2 (en) * 2002-08-16 2006-05-09 3F Therapeutics, Inc, Percutaneously delivered heart valve and delivery means thereof
EP1592367B1 (en) 2002-08-28 2016-04-13 HLT, Inc. Method and device for treating diseased valve
US6875231B2 (en) 2002-09-11 2005-04-05 3F Therapeutics, Inc. Percutaneously deliverable heart valve
AU2003263454A1 (en) 2002-09-19 2004-04-08 Petrus Besselink Vascular filter with improved strength and flexibility
CO5500017A1 (en) 2002-09-23 2005-03-31 3F Therapeutics Inc MITRAL PROTESTIC VALVE
US20040059412A1 (en) * 2002-09-25 2004-03-25 Lytle Thomas William Heart valve holder
US20040060161A1 (en) * 2002-09-27 2004-04-01 David Leal Methods of forming a heart valve stent
EP1562522B1 (en) 2002-10-01 2008-12-31 Ample Medical, Inc. Devices and systems for reshaping a heart valve annulus
US7591847B2 (en) 2002-10-10 2009-09-22 The Cleveland Clinic Foundation Stentless bioprosthetic valve having chordae for replacing a mitral valve
US7087064B1 (en) 2002-10-15 2006-08-08 Advanced Cardiovascular Systems, Inc. Apparatuses and methods for heart valve repair
BR0315392A (en) 2002-10-21 2005-08-23 Mitralign Inc Incrementing catheters and methods of performing annuloplasty
US8979923B2 (en) 2002-10-21 2015-03-17 Mitralign, Inc. Tissue fastening systems and methods utilizing magnetic guidance
WO2004037128A1 (en) 2002-10-24 2004-05-06 Boston Scientific Limited Venous valve apparatus and method
GB0225075D0 (en) * 2002-10-29 2002-12-04 Smiths Group Plc Valves
US20040082910A1 (en) 2002-10-29 2004-04-29 Constantz Brent R. Devices and methods for treating aortic valve stenosis
US7112219B2 (en) 2002-11-12 2006-09-26 Myocor, Inc. Devices and methods for heart valve treatment
US7247134B2 (en) 2002-11-12 2007-07-24 Myocor, Inc. Devices and methods for heart valve treatment
WO2004043265A2 (en) 2002-11-12 2004-05-27 Myocor, Inc. Devices and methods for heart valve treatment
AU2003287638A1 (en) 2002-11-13 2004-06-03 Rosengart, Todd, K. Apparatus and method for cutting a heart valve
AU2003294293A1 (en) 2002-11-13 2004-06-03 Viacor, Inc. Cardiac valve procedure methods and devices
US20040097979A1 (en) 2002-11-14 2004-05-20 Oleg Svanidze Aortic valve implantation device
US6945978B1 (en) 2002-11-15 2005-09-20 Advanced Cardiovascular Systems, Inc. Heart valve catheter
FR2847151B1 (en) 2002-11-15 2005-01-21 Claude Mialhe OCCLUSIVE DEVICE WITH MEDICAL OR SURGICAL DESTINATION
US7485143B2 (en) 2002-11-15 2009-02-03 Abbott Cardiovascular Systems Inc. Apparatuses and methods for heart valve repair
AU2003290979A1 (en) 2002-11-15 2004-06-15 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method and device for catheter-based repair of cardiac valves
US20040122515A1 (en) 2002-11-21 2004-06-24 Xi Chu Prosthetic valves and methods of manufacturing
US7316708B2 (en) 2002-12-05 2008-01-08 Cardiac Dimensions, Inc. Medical device delivery system
US8551162B2 (en) 2002-12-20 2013-10-08 Medtronic, Inc. Biologically implantable prosthesis
US6945957B2 (en) 2002-12-30 2005-09-20 Scimed Life Systems, Inc. Valve treatment catheter and methods
US20040133240A1 (en) 2003-01-07 2004-07-08 Cardiac Dimensions, Inc. Electrotherapy system, device, and method for treatment of cardiac valve dysfunction
US6830585B1 (en) 2003-01-14 2004-12-14 3F Therapeutics, Inc. Percutaneously deliverable heart valve and methods of implantation
US6997950B2 (en) 2003-01-16 2006-02-14 Chawla Surendra K Valve repair device
US6746463B1 (en) 2003-01-27 2004-06-08 Scimed Life Systems, Inc Device for percutaneous cutting and dilating a stenosis of the aortic valve
US7220271B2 (en) 2003-01-30 2007-05-22 Ev3 Inc. Embolic filters having multiple layers and controlled pore size
EP1594420A2 (en) 2003-01-31 2005-11-16 Koninklijke Philips Electronics N.V. Magnetic resonance compatible stent
US7314485B2 (en) 2003-02-03 2008-01-01 Cardiac Dimensions, Inc. Mitral valve device using conditioned shape memory alloy
US20040158321A1 (en) 2003-02-12 2004-08-12 Cardiac Dimensions, Inc. Method of implanting a mitral valve therapy device
US20040254600A1 (en) 2003-02-26 2004-12-16 David Zarbatany Methods and devices for endovascular mitral valve correction from the left coronary sinus
WO2004075789A2 (en) 2003-02-26 2004-09-10 Cook Incorporated PROTHESIS ADAPTED FOR PLACEDd UNDER EXTERNAL IMAGING
JP4624984B2 (en) 2003-03-12 2011-02-02 クック インコーポレイテッド Artificial valve that allows backflow
US7381210B2 (en) 2003-03-14 2008-06-03 Edwards Lifesciences Corporation Mitral valve repair system and method for use
US7524332B2 (en) 2003-03-17 2009-04-28 Cook Incorporated Vascular valve with removable support component
US7399315B2 (en) 2003-03-18 2008-07-15 Edwards Lifescience Corporation Minimally-invasive heart valve with cusp positioners
EP1608297A2 (en) 2003-03-18 2005-12-28 St. Jude Medical, Inc. Body tissue remodeling apparatus
US7988679B2 (en) 2003-03-18 2011-08-02 Navilyst Medical, Inc. Pressure responsive slit valve assembly for a plurality of fluids and uses thereof
US7909862B2 (en) 2003-03-19 2011-03-22 Cook Medical Technologies Llc Delivery systems and methods for deploying expandable intraluminal medical devices
ATE401843T1 (en) 2003-03-20 2008-08-15 Aortech Internat Plc VALVE
CH696185A5 (en) 2003-03-21 2007-02-15 Afksendiyos Kalangos Intraparietal reinforcement for aortic valve and reinforced valve has rod inserted in biological tissue or organic prosthesis with strut fixed to one end
SE0300854D0 (en) 2003-03-26 2003-03-26 Oeyvind Reitan Device for the treatment of a heart valve insufficiency
KR100466839B1 (en) 2003-03-28 2005-01-17 주식회사 사이언씨티 Aortic valve Repairing Apparatus Sets and Treatment Method Using The Same
US20060271081A1 (en) 2003-03-30 2006-11-30 Fidel Realyvasquez Apparatus and methods for valve repair
US20050075659A1 (en) 2003-03-30 2005-04-07 Fidel Realyvasquez Apparatus and methods for minimally invasive valve surgery
WO2004089253A1 (en) 2003-04-01 2004-10-21 Cook Incorporated Percutaneously deployed vascular valves
EP2163224A1 (en) 2003-04-08 2010-03-17 Cook Incorporated Intraluminal support device with graft
US8083707B2 (en) 2003-04-17 2011-12-27 Tosaya Carol A Non-contact damage-free ultrasonic cleaning of implanted or natural structures having moving parts and located in a living body
US7530995B2 (en) 2003-04-17 2009-05-12 3F Therapeutics, Inc. Device for reduction of pressure effects of cardiac tricuspid valve regurgitation
US7159593B2 (en) 2003-04-17 2007-01-09 3F Therapeutics, Inc. Methods for reduction of pressure effects of cardiac tricuspid valve regurgitation
US7175656B2 (en) 2003-04-18 2007-02-13 Alexander Khairkhahan Percutaneous transcatheter heart valve replacement
US6945996B2 (en) 2003-04-18 2005-09-20 Sedransk Kyra L Replacement mitral valve
US20040210240A1 (en) 2003-04-21 2004-10-21 Sean Saint Method and repair device for treating mitral valve insufficiency
WO2004093745A1 (en) 2003-04-23 2004-11-04 Cook Incorporated Devices kits, and methods for placing multiple intraluminal medical devices in a body vessel
ATE446061T1 (en) 2003-04-24 2009-11-15 Cook Inc ARTIFICIAL BLOOD VESSEL VALVE WITH IMPROVED FLOW BEHAVIOR
US20040267357A1 (en) 2003-04-30 2004-12-30 Allen Jeffrey W. Cardiac valve modification method and device
DE602004023350D1 (en) 2003-04-30 2009-11-12 Medtronic Vascular Inc Percutaneous inserted provisional valve
US20040220657A1 (en) 2003-05-02 2004-11-04 Cardiac Dimensions, Inc., A Washington Corporation Tissue shaping device with conformable anchors
US20040220654A1 (en) 2003-05-02 2004-11-04 Cardiac Dimensions, Inc. Device and method for modifying the shape of a body organ
US20040225356A1 (en) 2003-05-09 2004-11-11 Frater Robert W. Flexible heart valve
WO2004103222A1 (en) 2003-05-19 2004-12-02 Cook Incorporated Implantable medical device with constrained expansion
US8512403B2 (en) 2003-05-20 2013-08-20 The Cleveland Clinic Foundation Annuloplasty ring with wing members for repair of a cardiac valve
EP1628599A4 (en) 2003-05-27 2011-12-28 Viacor Inc Method and apparatus for improving mitral valve function
ATE481057T1 (en) 2003-05-28 2010-10-15 Cook Inc VALVE PROSTHESIS WITH VESSEL FIXING DEVICE
US7007396B2 (en) 2003-05-29 2006-03-07 Plc Medical Systems, Inc. Replacement heart valve sizing device
US7351259B2 (en) * 2003-06-05 2008-04-01 Cardiac Dimensions, Inc. Device, system and method to affect the mitral valve annulus of a heart
TW590007U (en) 2003-06-06 2004-06-01 Univ Tamkang Tri-leaflet mechanical heart valve
WO2005004753A1 (en) 2003-06-09 2005-01-20 3F Therapeutics, Inc. Atrioventricular heart valve and minimally invasive delivery systems thereof
US7537600B2 (en) 2003-06-12 2009-05-26 Boston Scientific Scimed, Inc. Valved embolic protection filter
US20040260394A1 (en) 2003-06-20 2004-12-23 Medtronic Vascular, Inc. Cardiac valve annulus compressor system
US7316706B2 (en) 2003-06-20 2008-01-08 Medtronic Vascular, Inc. Tensioning device, system, and method for treating mitral valve regurgitation
US7537592B2 (en) 2003-06-20 2009-05-26 Plc Medical Systems, Inc. Endovascular tissue removal device
WO2004112582A2 (en) 2003-06-20 2004-12-29 Plc Medical Systems, Inc. Endovascular tissue removal device
EP1648346A4 (en) 2003-06-20 2006-10-18 Medtronic Vascular Inc Valve annulus reduction system
US20070093869A1 (en) 2003-06-20 2007-04-26 Medtronic Vascular, Inc. Device, system, and method for contracting tissue in a mammalian body
US8052751B2 (en) 2003-07-02 2011-11-08 Flexcor, Inc. Annuloplasty rings for repairing cardiac valves
US7201772B2 (en) 2003-07-08 2007-04-10 Ventor Technologies, Ltd. Fluid flow prosthetic device
BRPI0412362A (en) 2003-07-08 2006-09-05 Ventor Technologies Ltd prosthetic implant devices particularly for transarterial transport in the treatment of aortic stenoses and implantation methods for such devices
WO2005007037A1 (en) 2003-07-11 2005-01-27 Vedic Biotechnology, Inc. Selective annuloplasty for atrio-ventricular heart valve regurgitation and devices therefor
WO2005007018A2 (en) 2003-07-16 2005-01-27 The Regents Of The University Of California Thin-film metal alloy biomedical implantable devices
NZ527025A (en) 2003-07-16 2007-01-26 David Peter Shaw Prosthetic valves for medical application
EP1673131B1 (en) 2003-07-17 2010-03-10 Cordis Corporation Devices for percutaneously treating aortic valve stenosis
US7744620B2 (en) 2003-07-18 2010-06-29 Intervalve, Inc. Valvuloplasty catheter
WO2005007036A1 (en) 2003-07-18 2005-01-27 Brivant Research & Development Limited A device for correcting inversion of the leaflets of a leaflet valve in the heart
EP1646332B1 (en) 2003-07-18 2015-06-17 Edwards Lifesciences AG Remotely activated mitral annuloplasty system
AU2004258942B2 (en) 2003-07-21 2009-12-03 The Trustees Of The University Of Pennsylvania Percutaneous heart valve
EP1670545B1 (en) 2003-07-22 2012-02-22 Corazon Technologies, Inc. Devices for treating aortic valve stenosis
AU2004258950B2 (en) 2003-07-23 2010-11-04 Viacor, Inc. Method and apparatus for improving mitral valve function
US7204255B2 (en) 2003-07-28 2007-04-17 Plc Medical Systems, Inc. Endovascular tissue removal device
DE10334868B4 (en) 2003-07-29 2013-10-17 Pfm Medical Ag Implantable device as a replacement organ valve, its manufacturing process and basic body and membrane element for it
US7951121B2 (en) * 2003-07-30 2011-05-31 Navilyst Medical, Inc. Pressure actuated valve with improved slit configuration
WO2005011535A2 (en) 2003-07-31 2005-02-10 Cook Incorporated Prosthetic valve for implantation in a body vessel
US7153324B2 (en) * 2003-07-31 2006-12-26 Cook Incorporated Prosthetic valve devices and methods of making such devices
FR2858543B1 (en) 2003-08-08 2006-02-03 Assist Publ Hopitaux De Paris AORTIC AND ANCILLARY RING FOR ITS INSTALLATION
DE10340265A1 (en) 2003-08-29 2005-04-07 Sievers, Hans-Hinrich, Prof. Dr.med. Prosthesis for the replacement of the aortic and / or mitral valve of the heart
US20050049692A1 (en) 2003-09-02 2005-03-03 Numamoto Michael J. Medical device for reduction of pressure effects of cardiac tricuspid valve regurgitation
WO2005027797A1 (en) 2003-09-23 2005-03-31 Ersin Erek A mitral web apparatus for mitral valve insufficiencies
EG24012A (en) 2003-09-24 2008-03-23 Wael Mohamed Nabil Lotfy Valved balloon stent
US20050075725A1 (en) 2003-10-02 2005-04-07 Rowe Stanton J. Implantable prosthetic valve with non-laminar flow
US20050075712A1 (en) 2003-10-06 2005-04-07 Brian Biancucci Minimally invasive valve replacement system
CA2545874C (en) 2003-10-06 2012-02-21 3F Therapeutics, Inc. Minimally invasive valve replacement system
US10219899B2 (en) 2004-04-23 2019-03-05 Medtronic 3F Therapeutics, Inc. Cardiac valve replacement systems
WO2005039428A2 (en) 2003-10-17 2005-05-06 Edwards Lifesciences Ag Heart valve leaflet locator
US7004176B2 (en) 2003-10-17 2006-02-28 Edwards Lifesciences Ag Heart valve leaflet locator
US7258698B2 (en) 2003-10-17 2007-08-21 Medtronic, Inc. Prosthetic heart valve sizer assembly with flexible sizer body
ITBO20030631A1 (en) 2003-10-23 2005-04-24 Roberto Erminio Parravicini VALVULAR PROSTHETIC EQUIPMENT, IN PARTICULAR FOR HEART APPLICATIONS.
DE10350287A1 (en) 2003-10-24 2005-05-25 Deutsche Institute für Textil- und Faserforschung Stuttgart - Stiftung des öffentlichen Rechts Cardiovascular implant, for use as a vascular or heart valve replacement, comprises a non-resorbable polymer formed as a microfiber fleece that allows colonization by a cells
US7347869B2 (en) 2003-10-31 2008-03-25 Cordis Corporation Implantable valvular prosthesis
US7070616B2 (en) 2003-10-31 2006-07-04 Cordis Corporation Implantable valvular prosthesis
US7416530B2 (en) 2003-11-04 2008-08-26 L & P 100 Limited Medical devices
WO2005046530A1 (en) 2003-11-12 2005-05-26 Medtronic Vascular, Inc. Coronary sinus approach for repair of mitral valve reguritation
US7655040B2 (en) 2003-11-12 2010-02-02 Medtronic Vascular, Inc. Cardiac valve annulus reduction system
WO2005048883A1 (en) 2003-11-13 2005-06-02 Fidel Realyvasquez Methods and apparatus for valve repair
US7740656B2 (en) 2003-11-17 2010-06-22 Medtronic, Inc. Implantable heart valve prosthetic devices having intrinsically conductive polymers
WO2005055811A2 (en) 2003-12-02 2005-06-23 Fidel Realyvasquez Methods and apparatus for mitral valve repair
AU2004296816A1 (en) 2003-12-04 2005-06-23 The Brigham And Women's Hospital, Inc. Aortic valve annuloplasty rings
US7186265B2 (en) 2003-12-10 2007-03-06 Medtronic, Inc. Prosthetic cardiac valves and systems and methods for implanting thereof
US20050177228A1 (en) 2003-12-16 2005-08-11 Solem Jan O. Device for changing the shape of the mitral annulus
AU2004298762A1 (en) 2003-12-16 2005-06-30 Edwards Lifesciences Ag Device for changing the shape of the mitral annulus
US20050137449A1 (en) 2003-12-19 2005-06-23 Cardiac Dimensions, Inc. Tissue shaping device with self-expanding anchors
US7837728B2 (en) 2003-12-19 2010-11-23 Cardiac Dimensions, Inc. Reduced length tissue shaping device
US8128681B2 (en) 2003-12-19 2012-03-06 Boston Scientific Scimed, Inc. Venous valve apparatus, system, and method
US7854761B2 (en) 2003-12-19 2010-12-21 Boston Scientific Scimed, Inc. Methods for venous valve replacement with a catheter
US20050137450A1 (en) 2003-12-19 2005-06-23 Cardiac Dimensions, Inc., A Washington Corporation Tapered connector for tissue shaping device
US7794496B2 (en) 2003-12-19 2010-09-14 Cardiac Dimensions, Inc. Tissue shaping device with integral connector and crimp
US7261732B2 (en) 2003-12-22 2007-08-28 Henri Justino Stent mounted valve
US20050137696A1 (en) 2003-12-23 2005-06-23 Sadra Medical Apparatus and methods for protecting against embolization during endovascular heart valve replacement
US7431726B2 (en) 2003-12-23 2008-10-07 Mitralign, Inc. Tissue fastening systems and methods utilizing magnetic guidance
US7329279B2 (en) 2003-12-23 2008-02-12 Sadra Medical, Inc. Methods and apparatus for endovascularly replacing a patient's heart valve
US7959666B2 (en) 2003-12-23 2011-06-14 Sadra Medical, Inc. Methods and apparatus for endovascularly replacing a heart valve
US7381219B2 (en) 2003-12-23 2008-06-03 Sadra Medical, Inc. Low profile heart valve and delivery system
US20050137686A1 (en) 2003-12-23 2005-06-23 Sadra Medical, A Delaware Corporation Externally expandable heart valve anchor and method
US20050137694A1 (en) 2003-12-23 2005-06-23 Haug Ulrich R. Methods and apparatus for endovascularly replacing a patient's heart valve
US9526609B2 (en) 2003-12-23 2016-12-27 Boston Scientific Scimed, Inc. Methods and apparatus for endovascularly replacing a patient's heart valve
US8603160B2 (en) 2003-12-23 2013-12-10 Sadra Medical, Inc. Method of using a retrievable heart valve anchor with a sheath
US7748389B2 (en) 2003-12-23 2010-07-06 Sadra Medical, Inc. Leaflet engagement elements and methods for use thereof
US8182528B2 (en) 2003-12-23 2012-05-22 Sadra Medical, Inc. Locking heart valve anchor
US7780725B2 (en) 2004-06-16 2010-08-24 Sadra Medical, Inc. Everting heart valve
US7445631B2 (en) 2003-12-23 2008-11-04 Sadra Medical, Inc. Methods and apparatus for endovascularly replacing a patient's heart valve
US7824442B2 (en) 2003-12-23 2010-11-02 Sadra Medical, Inc. Methods and apparatus for endovascularly replacing a heart valve
US8840663B2 (en) 2003-12-23 2014-09-23 Sadra Medical, Inc. Repositionable heart valve method
US8343213B2 (en) 2003-12-23 2013-01-01 Sadra Medical, Inc. Leaflet engagement elements and methods for use thereof
WO2005070343A1 (en) 2003-12-23 2005-08-04 Laboratoires Perouse Kit which is intended to be implanted in a conduit
US20050137691A1 (en) 2003-12-23 2005-06-23 Sadra Medical Two piece heart valve and anchor
US20050149181A1 (en) 2004-01-07 2005-07-07 Medtronic, Inc. Bileaflet prosthetic valve and method of manufacture
US20050159810A1 (en) 2004-01-15 2005-07-21 Farzan Filsoufi Devices and methods for repairing cardiac valves
WO2005069850A2 (en) 2004-01-15 2005-08-04 Macoviak John A Trestle heart valve replacement
US7488346B2 (en) 2004-01-21 2009-02-10 The Cleveland Clinic Foundation Method and apparatus for replacing a mitral valve and an aortic valve with a single homograft
JP4494421B2 (en) 2004-01-22 2010-06-30 アドヴァンスト サージカル デザイン アンド マニュファクチャー リミテッド Heart valve
US7871435B2 (en) 2004-01-23 2011-01-18 Edwards Lifesciences Corporation Anatomically approximate prosthetic mitral heart valve
US7320705B2 (en) 2004-01-23 2008-01-22 James Quintessenza Bicuspid pulmonary heart valve and method for making same
US7597711B2 (en) 2004-01-26 2009-10-06 Arbor Surgical Technologies, Inc. Heart valve assembly with slidable coupling connections
JP4651625B2 (en) 2004-01-27 2011-03-16 メッド・インスティテュート・インコーポレイテッド Fixed barbs for attachment to medical prostheses
JP4403183B2 (en) 2004-02-05 2010-01-20 チルドレンズ・メディカル・センター・コーポレイション Transcatheter delivery of replacement heart valves
US7311730B2 (en) 2004-02-13 2007-12-25 Shlomo Gabbay Support apparatus and heart valve prosthesis for sutureless implantation
US7955375B2 (en) 2004-02-20 2011-06-07 Cook Medical Technologies Llc Prosthetic valve with spacing member
US7717930B2 (en) 2004-02-27 2010-05-18 Cook Incorporated Valvulotome with a cutting edge
CN101683291A (en) 2004-02-27 2010-03-31 奥尔特克斯公司 Prosthetic heart valve delivery systems and methods
US20050203549A1 (en) 2004-03-09 2005-09-15 Fidel Realyvasquez Methods and apparatus for off pump aortic valve replacement with a valve prosthesis
WO2005087140A1 (en) 2004-03-11 2005-09-22 Percutaneous Cardiovascular Solutions Pty Limited Percutaneous heart valve prosthesis
WO2005087139A1 (en) 2004-03-15 2005-09-22 Baker Medical Research Institute Treating valve failure
WO2005089674A1 (en) 2004-03-15 2005-09-29 Medtronic Vascular Inc. Radially crush-resistant stent
US20050228494A1 (en) 2004-03-29 2005-10-13 Salvador Marquez Controlled separation heart valve frame
US7449027B2 (en) 2004-03-29 2008-11-11 Cook Incorporated Modifying fluid flow in a body vessel lumen to promote intraluminal flow-sensitive processes
US7993397B2 (en) 2004-04-05 2011-08-09 Edwards Lifesciences Ag Remotely adjustable coronary sinus implant
US20060013855A1 (en) 2004-04-05 2006-01-19 Medivas, Llc Bioactive stents for type II diabetics and methods for use thereof
US20050222675A1 (en) 2004-04-06 2005-10-06 Sauter Joseph A Implantable prosthetic heart valve comprising a valve body and a tubular vascular graft
US8349001B2 (en) 2004-04-07 2013-01-08 Medtronic, Inc. Pharmacological delivery implement for use with cardiac repair devices
WO2005099628A2 (en) 2004-04-13 2005-10-27 Cook Incorporated Implantable frame with variable compliance
US20050240202A1 (en) 2004-04-21 2005-10-27 Hani Shennib Devices and methods of repairing cardiac valves
BRPI0510107A (en) 2004-04-23 2007-09-25 3F Therapeutics Inc implantable protein valve
US20050240255A1 (en) 2004-04-23 2005-10-27 Schaeffer Darin G Carrier-Based Delivery System for Intraluminal Medical Devices
US7641686B2 (en) 2004-04-23 2010-01-05 Direct Flow Medical, Inc. Percutaneous heart valve with stentless support
US7951196B2 (en) 2004-04-29 2011-05-31 Edwards Lifesciences Corporation Annuloplasty ring for mitral valve prolapse
US20050244460A1 (en) 2004-04-29 2005-11-03 Ivan Alferiev Biodegradable crosslinking strategies using triglycidyl amine (TGA)
US20050256566A1 (en) 2004-05-03 2005-11-17 Shlomo Gabbay Apparatus and method for improving ventricular function
US7374573B2 (en) 2004-05-03 2008-05-20 Shlomo Gabbay System and method for improving ventricular function
EP2422751A3 (en) 2004-05-05 2013-01-02 Direct Flow Medical, Inc. Unstented heart valve with formed in place support structure
US7717951B2 (en) 2004-05-06 2010-05-18 Cook Incorporated Delivery system that facilitates visual inspection of an intraluminal medical device
US20060122692A1 (en) 2004-05-10 2006-06-08 Ran Gilad Stent valve and method of using same
US20060095115A1 (en) 2004-05-10 2006-05-04 Youssef Bladillah Stent and method of manufacturing same
US20060122686A1 (en) 2004-05-10 2006-06-08 Ran Gilad Stent and method of manufacturing same
US20060122693A1 (en) 2004-05-10 2006-06-08 Youssef Biadillah Stent valve and method of manufacturing same
EP1750592B1 (en) 2004-05-14 2016-12-28 Evalve, Inc. Locking mechanisms for fixation devices
WO2005112831A2 (en) 2004-05-17 2005-12-01 Fidel Realyvasquez Method and apparatus for percutaneous valve repair
WO2005118019A1 (en) 2004-05-28 2005-12-15 Cook Incorporated Implantable bioabsorbable valve support frame
US7803182B2 (en) 2004-05-28 2010-09-28 Cordis Corporation Biodegradable vascular device with buffering agent
US7785615B2 (en) 2004-05-28 2010-08-31 Cordis Corporation Biodegradable medical implant with encapsulated buffering agent
GB0414099D0 (en) 2004-06-23 2004-07-28 Univ Glasgow Biocompatible layered structures and methods for their manufacture
US20050288778A1 (en) 2004-06-29 2005-12-29 Emanuel Shaoulian Selectively adjustable cardiac valve implants
EP1773251A1 (en) 2004-06-29 2007-04-18 The Cleveland Clinic Foundation Prosthetic cardiac valve and method for making same
US7276078B2 (en) 2004-06-30 2007-10-02 Edwards Lifesciences Pvt Paravalvular leak detection, sealing, and prevention
US7462191B2 (en) 2004-06-30 2008-12-09 Edwards Lifesciences Pvt, Inc. Device and method for assisting in the implantation of a prosthetic valve
EP1781179A1 (en) 2004-07-06 2007-05-09 Baker Medical Research Institute Treating valvular insufficiency
US7513864B2 (en) 2004-07-09 2009-04-07 Kantrowitz Allen B Synchronization system between aortic valve and cardiac assist device
JP2008506470A (en) 2004-07-15 2008-03-06 ミカーディア コーポレーション Implant for forming a heart valve (implant) and method for forming the same
US8034102B2 (en) 2004-07-19 2011-10-11 Coroneo, Inc. Aortic annuloplasty ring
US7422607B2 (en) 2004-08-24 2008-09-09 Oviatt Henry W Anti-calcification treatments for heart valves and vascular grafts
AU2005280151A1 (en) 2004-08-26 2006-03-09 Cook Incorporated Delivery system with controlled frictional properties
EP1786367B1 (en) 2004-08-27 2013-04-03 Cook Medical Technologies LLC Placement of multiple intraluminal medical devices within a body vessel
CA2578706A1 (en) 2004-09-01 2006-03-16 Cook Incorporated Delivery system which facilitates hydration of an intraluminal medical device
FR2874813B1 (en) 2004-09-07 2007-06-22 Perouse Soc Par Actions Simpli VALVULAR PROSTHESIS
US20060052867A1 (en) 2004-09-07 2006-03-09 Medtronic, Inc Replacement prosthetic heart valve, system and method of implant
CN1745727A (en) 2004-09-08 2006-03-15 王蓉珍 Intercurrent artificial heart valve, its implanting and recovering device
JP4589395B2 (en) 2004-09-10 2010-12-01 クック インコーポレイテッド Prosthetic valve with holes
CN101056596B (en) 2004-09-14 2011-08-03 爱德华兹生命科学股份公司 Device and method for treatment of heart valve regurgitation
WO2006034245A2 (en) 2004-09-20 2006-03-30 Cardiac Dimensions, Inc. Percutaneous mitral valve annuloplasty delivery system
US20060064174A1 (en) 2004-09-22 2006-03-23 Reza Zadno Implantable valves and methods of making the same
US7850704B2 (en) 2004-09-27 2010-12-14 Theranova, Llc Method and apparatus for anchoring implants
US6951571B1 (en) 2004-09-30 2005-10-04 Rohit Srivastava Valve implanting device
US20060074483A1 (en) 2004-10-01 2006-04-06 Schrayer Howard L Method of treatment and devices for the treatment of left ventricular failure
WO2006041505A1 (en) 2004-10-02 2006-04-20 Huber Christoph Hans Methods and devices for repair or replacement of heart valves or adjacent tissue without the need for full cardiopulmonary support
WO2006041972A2 (en) 2004-10-06 2006-04-20 Cook Incorporated Medical device with bioactive agent
US20060085060A1 (en) 2004-10-15 2006-04-20 Campbell Louis A Methods and apparatus for coupling an allograft tissue valve and graft
WO2006050459A2 (en) 2004-10-28 2006-05-11 Cook Incorporated Methods and systems for modifying vascular valves
US7458987B2 (en) 2004-10-29 2008-12-02 Cook Incorporated Vascular valves having implanted and target configurations and methods of preparing the same
US7641687B2 (en) 2004-11-02 2010-01-05 Carbomedics Inc. Attachment of a sewing cuff to a heart valve
JP2008518706A (en) 2004-11-04 2008-06-05 エル・アンド・ピー・100・リミテッド Medical device
US20060100697A1 (en) 2004-11-10 2006-05-11 Casanova R M Shape memory annuloplasty ring and holder
US20060167468A1 (en) 2004-11-12 2006-07-27 Shlomo Gabbay Implantation system and method for loading an implanter with a prosthesis
US7744642B2 (en) 2004-11-19 2010-06-29 Biomedical Research Associates, Inc. Prosthetic venous valves
WO2006054107A2 (en) 2004-11-19 2006-05-26 Medtronic Inc. Method and apparatus for treatment of cardiac valves
US20060135967A1 (en) 2004-11-22 2006-06-22 Fidel Realyvasquez Method and apparatus for attaching a valve prosthesis
US20060161249A1 (en) 2004-11-22 2006-07-20 Fidel Realyvasquez Ring-shaped valve prosthesis attachment device
US20060111774A1 (en) 2004-11-24 2006-05-25 Samkov Alexander V Low noise heart valve prosthesis and method for operation
US20060116572A1 (en) 2004-12-01 2006-06-01 Case Brian C Sensing delivery system for intraluminal medical devices
US20060161248A1 (en) 2004-12-01 2006-07-20 Case Brian C Medical device with leak path
WO2006063181A1 (en) 2004-12-06 2006-06-15 Surmodics, Inc. Multifunctional medical articles
US20060127443A1 (en) 2004-12-09 2006-06-15 Helmus Michael N Medical devices having vapor deposited nanoporous coatings for controlled therapeutic agent delivery
CN101076290B (en) 2004-12-09 2011-11-23 铸造品股份有限公司 Aortic valve repair
US7211110B2 (en) 2004-12-09 2007-05-01 Edwards Lifesciences Corporation Diagnostic kit to assist with heart valve annulus adjustment
US7410497B2 (en) 2004-12-14 2008-08-12 Boston Scientific Scimed, Inc. Stimulation of cell growth at implant surfaces
SE0403046D0 (en) 2004-12-15 2004-12-15 Medtentia Ab A device and method for improving the function of a heart valve
EP1841383A1 (en) 2004-12-15 2007-10-10 Mednua Limited A medical device suitable for use in treatment of a valve
US7758640B2 (en) 2004-12-16 2010-07-20 Valvexchange Inc. Cardiovascular valve assembly
WO2006066148A2 (en) 2004-12-16 2006-06-22 Carlos Ruiz A heart valve and method for insertion of the heart valve into a bodily vessel
US20060217794A1 (en) 2004-12-16 2006-09-28 Carlos Ruiz Separable sheath and method for insertion of a medical device into a bodily vessel using a separable sheath
EP1848368A1 (en) 2004-12-20 2007-10-31 Cook Incorporated Intraluminal support frame and medical devices including the support frame
US7575594B2 (en) 2004-12-30 2009-08-18 Sieracki Jeffrey M Shock dampening biocompatible valve
DE102005003632A1 (en) 2005-01-20 2006-08-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Catheter for the transvascular implantation of heart valve prostheses
US7854755B2 (en) 2005-02-01 2010-12-21 Boston Scientific Scimed, Inc. Vascular catheter, system, and method
US20060173490A1 (en) 2005-02-01 2006-08-03 Boston Scientific Scimed, Inc. Filter system and method
US8012198B2 (en) * 2005-06-10 2011-09-06 Boston Scientific Scimed, Inc. Venous valve, system, and method
WO2007097983A2 (en) 2006-02-14 2007-08-30 Sadra Medical, Inc. Systems and methods for delivering a medical implant
JP5604110B2 (en) 2007-02-05 2014-10-08 ボストン サイエンティフィック リミテッド System for delivering a valve
FR2915678B1 (en) 2007-05-02 2010-04-16 Lapeyre Ind Llc MECHANICAL PROTHETIC CARDIAC VALVE
US8747458B2 (en) 2007-08-20 2014-06-10 Medtronic Ventor Technologies Ltd. Stent loading tool and method for use thereof
CA2961051C (en) 2008-02-29 2020-01-14 Edwards Lifesciences Corporation Expandable member for deploying a prosthetic device

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851000A (en) * 1987-07-31 1989-07-25 Pacific Biomedical Holdings, Ltd. Bioprosthetic valve stent
US8932349B2 (en) * 2004-09-02 2015-01-13 Boston Scientific Scimed, Inc. Cardiac valve, system, and method

Also Published As

Publication number Publication date
US7566343B2 (en) 2009-07-28
EP2450008B1 (en) 2015-10-21
US20150088252A1 (en) 2015-03-26
ES2379180T3 (en) 2012-04-23
EP2450008A2 (en) 2012-05-09
US20060047338A1 (en) 2006-03-02
US20110301705A1 (en) 2011-12-08
US8932349B2 (en) 2015-01-13
EP1788984B1 (en) 2012-02-15
US8002824B2 (en) 2011-08-23
WO2006031469A1 (en) 2006-03-23
EP1788984A1 (en) 2007-05-30
US9918834B2 (en) 2018-03-20
EP2450008A3 (en) 2013-08-21
US20090287298A1 (en) 2009-11-19
ATE545389T1 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
US9918834B2 (en) Cardiac valve, system and method
US9861473B2 (en) Valve apparatus, system and method
US10226344B2 (en) Percutaneous valve, system and method
US10869764B2 (en) Venous valve apparatus, system, and method
EP2520253B1 (en) Valve apparatus, system and method
JP4837678B2 (en) System including catheter with cutting edge
US8672997B2 (en) Valve with sinus
US20140379068A1 (en) Circulatory Valve, System and Method

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION